

# THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office


February 10, 2004

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM  
THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK  
OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT  
APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A  
FILING DATE.

APPLICATION NUMBER: 60/367,863

FILING DATE: March 25, 2002

RELATED PCT APPLICATION NUMBER: PCT/US03/08880



By Authority of the  
COMMISSIONER OF PATENTS AND TRADEMARKS

*T. Wallace*  
T. WALLACE  
Certifying Officer

**PRIORITY  
DOCUMENT**

SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)

03-28-02

A/PROV

Customer Number: 000959

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Yocum, *et al.*

Attorney

Docket No. BGI-152-2

For: Methods and Organisms for Production of B6 Vitamers

Commissioner for Patents  
 Box Provisional Patent Application  
 Washington, D.C. 20231

## CERTIFICATION UNDER 37 CFR 1.10

Date of Deposit: March 25, 2002Mailing Label Number: EL 941 548 122 US

I hereby certify that this Cover Sheet for Filing Provisional Application (37 C.F.R. §1.51(2)(i)) and the documents referred to as attached therein are being deposited with the United States Postal Service on the date indicated above in an envelope as "Express Mail Post Office to Addressee" service under 37 CFR 1.10 and addressed to the Commissioner for Patents, Box Provisional Patent Application, Washington, D.C. 20231.

Ilidio P. Cardoso

Name of Person Mailing Paper



Signature of Person Mailing Paper

## COVER SHEET FOR FILING PROVISIONAL PATENT APPLICATION

Dear Sir:

The accompanying application, entitled "Methods and Organisms for Production of B6 Vitamers," is a provisional patent application under 37 C.F.R. §1.51(c) and §1.53(c).

1. ☒ The name(s) and address(es) of the inventor(s) of this application is/are as follows:

1	Yocum	R.	Rogers	4 Orchard Lane, Lexington, Massachusetts 02420
2	Williams	Mark	K.	58 School Street, Revere, Massachusetts 02151
3	Pero	Janice	G.	20 Solomon Pierce Road, Lexington, Massachusetts 02420

2. ☒ The following documents are enclosed:

- ☒ 28 page(s) of Specification
- ☒ 6 page(s) of Claims
- ☒ 1 page(s) of Abstract
- ☒ 12 page(s) of Sequence Listing
- ☒ 7 sheets of Informal Drawings; and
- ☒ Return postcard.

03/25/02



60367863-032502

1c996 U.S. PTO  
60/367863

3. ☒ The fee for filing this provisional application, as set forth in 37 CFR 1.16(k), is \$160.00.

- a. ☒ A check for this filing fee is enclosed.
- b. ☐ Charge the filing fee to Deposit Account No. \_\_\_\_\_.  
(A duplicate copy of this sheet is enclosed.)
- c. ☐ The filing fee is not being paid at this time.


4. ☒ Please charge any fee deficiencies associated with this filing to Deposit Account No. 12-0080. A duplicate copy of this sheet is enclosed.

5. ☒ Please address all future communications to: **Customer Number: 000959** whose address is:

Lahive & Cockfield, LLP  
28 State Street  
Boston, MA 02109

and direct telephone calls to: Elizabeth A. Hanley, (617) 227-7400

Respectfully submitted,



Debra J. Milasincic, Esq.  
Reg. No. 46,931  
Attorney for Applicants

March 25, 2002  
Date

LAHIVE & COCKFIELD, LLP  
28 State Street  
Boston, MA 02109  
Tel. (617) 227-7400

60367863-032502

## METHODS AND ORGANISMS FOR PRODUCTION OF B6 VITAMERS

### Background of the Invention

5 Vitamin B6, also known as pyridoxine or pyridoxol (PN), or one of a  
number of closely related compounds, is an essential dietary nutrient for most, if not all,  
animals, while many micro-organisms (bacteria, fungi, algae, etc.) and plants are  
capable of synthesizing their own vitamin B6 or compound(s) related to vitamin B6.  
When an animal ingests PN or a related compound that has vitamin B6 activity, the  
10 compound is converted ultimately into pyridoxal phosphate (PLP) and/or pyridoxamine  
phosphate (PMP), which are the active forms of vitamin B6 in all living organisms. PLP  
acts as a cofactor for many important or essential enzymes in all living organisms,  
including transaminases, racemases, and decarboxylases. PLP and PMP are easily  
interconverted by ubiquitous transaminases.

15 Vitamin B6 is of commercial importance in vitamin pills, pharmaceutical  
applications, and as an animal feed additive that enhances growth or desirable growth  
characteristics in farm and domestic animals. The currently used commercial process  
for producing vitamin B6 is a synthetic chemical process. However, a fermentation  
process using a microorganism (see US Patent application No. 09/667,569, filed  
20 September 21, 2000, hereby incorporated in its entirety by reference) or a biosynthetic  
process using a plant species can be more cost effective in the long run, and may be  
environmentally more attractive.

The biosynthetic pathway for PLP in *E. coli* has been elucidated  
(reviewed in Mittengruber, G., (2001) *J. Mol. Microbiol. Biotechnol.* 3(1): 1-20; Cane,  
25 D.E., et al. (2000) *J. Am. Chem. Soc.* 122: 4213-4214; Man, T-K, et al., (1996) *J.*  
*Bacteriol.* 178: 2445-2449). Enzymes encoded by the genes *epd*, *pdxB*, *pdxF*, and *pdxA*  
lead to synthesis of the precursor 1-hydroxy-3-amino acetone phosphate from erythrose-  
4-phosphate and glutamate. The enzyme encoded by *dxs* leads to the precursor 5'-  
deoxyxylulose phosphate from glycolytic intermediates. The enzyme encoded by *pdxJ*  
30 then catalyzes the chemical coupling of the two precursors to give pyridoxol phosphate  
(also called pyridoxine phosphate or PNP). PNP is then oxidized to the active form,  
PLP, by the enzyme encoded by *pdxH*. This biosynthetic pathway to PLP in *E. coli*, as  
well as closely related pathways, are referred to herein as the Type A Pathway. Partially  
characterized mutants of *E. coli* have been described that produce about three- to seven-  
35 fold more vitamin B6-related compounds than the parent strain (Dempsey and Arcement  
(1971) *J. Bacteriol.* 107(2): 580-582). Partially characterized mutants of *B. subtilis* have  
been reported that produce 1 - 5 mg/l vitamin B6, but it was not stated what level the

60367863-032502

parent strain produced (Pflug, W., and Lingens, F., (1978) Hoppe-Seyler's Z. Physiol. Chem. 359: 559-570). Notably, these organisms were not recombinantly produced.

A second biosynthetic pathway for vitamin B6, referred to herein as the Type B pathway, may exist in some organisms other than *E. coli* (Mittengruber, G., (2001) *J. Mol. Microbiol. Biotechnol.* 3(1):1-20). In particular, some fungi (for example from the genera *Cercospora*, *Neurospora*, *Aspergillus* and *Saccharomyces*), some bacteria (for example *B. subtilis* and *Staphylococcus aureus*), and all plants for which data exists do not contain any genes that are highly homologous to *E. coli* *pdxA* and *pdxJ*. Instead, these organisms contain genes that are homologous to *Cercospora* genes named *SOR* (or *SNZ*) and *SNO*. In *Saccharomyces*, these homologs are called *PDX1* and *PDX2*, respectively, and in *B. subtilis*, these homologs are named *yaaD* and *yaaE*, respectively. In *B. subtilis*, there have been no reports as to whether *yaaD* or *yaaE* are actually involved in PLP biosynthesis. Protein or DNA sequence homology alone is not sufficient to establish biological function. For example, *B. subtilis* contains a gene, *yhaF*, that encodes a protein that is significantly homologous to *E. coli* *pdxF*. However, when *yhaF* is mutated, the resulting mutant *B. subtilis* strain is a serine auxotroph, but not a PL auxotroph (see Example 3, below). Thus, the identification of a gene or genes involved in PLP biosynthesis in any given organism can not be done using sequence homology alone.

Results from <sup>13</sup>C and <sup>15</sup>N labeling studies suggest that the precursors that provide the carbon and nitrogen atoms in PL and related compounds are different in *E. coli* and *Saccharomyces cerevisiae* (Gupta, R., et al. (2001) *J. Am Chem. Soc.* 123: 11353-11359; Tayuza, K., et al. (1995) *Biochim. Biophys. Acta* 1244: 113-116.) However, the identity of the precursors for PL and related compounds in *S. cerevisiae* is not yet known. Since most micro-organisms for which the entire genome sequence is known (for example *E. coli*, *S. cerevisiae* and *B. subtilis*) have either *pdxA* and *pdxJ* homologs or *SOR* and *SNO* homologs, but not both, it appears that most organisms that are capable of synthesizing PLP have either the well characterized Type A Pathway (for example *E. coli*, *Salmonella typhimurium*, and many other genera), or a distinctly different and incompletely characterized pathway, e.g., the Type B Pathway. Specifically, members of the genera *Cercospora*, *Neurospora*, *Aspergillus*, *Saccharomyces*, *Bacillus*, *Arabidopsis*, and many other genera, appear to have a Type B pathway, and are lacking genes involved in the Type A Pathway. The intermediate compounds in the Type B Pathway have not yet been elucidated, although the final product must be PLP (as for the Type A Pathway) or PMP, since these are the active forms of vitamin B6 in all known organisms.

50367863-032502

Summary of the Invention

The present invention is based, at least in part, on the discovery of key enzyme-encoding genes of the B6 vitamer biosynthetic pathways in *Bacillus subtilis*. In particular, the invention is based, at least in part, on the discovery that the *yaaD* and *yaaE* genes of *B. subtilis* are required for B6 vitamer synthesis. Deletion of a portion of the *yaaD* and *yaaE* genes (which are adjacent in an operon, *e.g.*, the *yaaDE* operon) leads to PL auxotrophy. Overexpression of the *yaaDE* operon or the deregulation of the expression of the *yaaD* or *yaaE* genes leads to significantly increased production of B6 vitamers in, *e.g.*, *B. subtilis* strains. The *B. subtilis yaaDE* operon is required for pyridoxal phosphate (PLP) biosynthesis, an active form of vitamin B6 in all living organisms. The present invention describes that the expression of the *B. subtilis yaaDE* operon is a rate limiting step for production of compounds related to vitamin B6 in a wild type strain.

Accordingly, the present invention features methods of producing B6 vitamers, including, but not limited to, pyridoxine (or pyridoxol (PN)), pyridoxal (PL), pyridoxamine (PM), or the 5' phosphorylated derivatives of any of the three aforementioned compounds (PNP, PLP, and PMP), using organisms in which the B6 vitamer pathway has been manipulated such that B6 vitamers are produced. Such methods include culturing a microorganism that overexpresses at least one B6 vitamer biosynthetic enzyme (*e.g.*, at least one of the *yaaD* or *yaaE* gene products), under conditions such that the B6 vitamer is produced. The production methods of the present invention further can include recovering the B6 vitamer.

The instant invention also features genetically modified organisms (*i.e.*, organisms that contain one or more modifications or mutations in the genome) that are capable of producing significantly more of a B6 vitamer than an unmodified parent organism. In particular, this invention features micro-organisms (including, for example, but not limited to, bacteria, yeasts, fungi, and algae) or macro-organisms such as plants that, when genetically modified, produce an increased amount, *e.g.*, at least about 10-fold more of a B6 vitamer, than the unmodified parent organism. Specific examples are given herein in which *Bacillus subtilis* and *Escherichia coli* strains have been genetically modified such that they produce significant amounts of a B6 vitamer. Accordingly, the present invention features organisms that have been genetically modified to increase the activity of one or more enzymes that catalyze(s) a step in the biosynthesis of a B6 vitamer, such that B6 vitamer production from said modified organism is increased compared to B6 production in an unmodified parent organism.

Yet another aspect of the invention features recombinant microorganisms which overexpress at least one *Bacillus* (*e.g.*, *B. subtilis*) B6 vitamer biosynthetic

60367863-032502

enzyme (e.g., at least one of the *yaaD* or *yaaE* gene products) are described. In one embodiment, the recombinant microorganism is Gram positive (e.g., microorganisms belonging to the genus *Bacillus*, *Corynebacterium*, *Lactobacillus*, *Lactococci* or *Streptomyces*). In another embodiment, the recombinant microorganism is Gram  
5 negative. Particularly preferred is a *Bacillus* recombinant microorganism (e.g., *Bacillus licheniformis*, *Bacillus amyloliquefaciens*, *Bacillus subtilis*, *Bacillus pumilus*, *Bacillus halodurans*, and the like).

Recombinant vectors that contain genes encoding *Bacillus* B6 vitamer biosynthetic enzymes, e.g., *yaaD* or *yaaE* genes, are also described.

10 Other features and advantages of the invention will be apparent from the following detailed description and claims.

#### Brief Description of the Drawings

15 *Figure 1* depicts the chemical structures of vitamin B6 and related compounds.

*Figure 2* depicts the biosynthetic pathway for PLP in *E. coli*.

*Figure 3* depicts the standard curves generated by *Saccharomyces unarum* strain ATCC 9080 after feeding serial dilutions of PN, PL, and PM (as  
20 described in Example 1).

*Figure 4* is a schematic representation of the plasmid pDX1F.

*Figure 5* is a schematic representation of the plasmid pDX11F.

*Figure 6* is a schematic representation of the plasmid pDX14R.

*Figure 7* is a schematic representation of the plasmid pDX17R.  
25

#### Detailed Description of the Invention

The present invention is based, at least in part, on the identification of *Bacillus* (e.g., *B. subtilis*) genes that encode essential enzymes of the B6 vitamer biosynthetic pathway. In particular, the present invention features methods based on  
30 manipulation of the B6 vitamer biosynthetic pathway in a microorganism such that certain desirable compounds are produced.

In particular, the invention is based, at least in part, on the discovery that the *yaaD* and *yaaE* genes of *B. subtilis* are required for B6 vitamer synthesis, including, but not limited to, pyridoxine (or pyridoxol (PN)), pyridoxal (PL), pyridoxamine (PM),  
35 or the 5' phosphorylated derivatives of any of the three aforementioned compounds (PNP, PLP, and PMP). The *yaaD* and *yaaE* genes are adjacent on an operon, e.g., the *yaaDE* operon. The *yaaD* and *yaaE* genes encode the YaaD and Yaa E proteins,

respectively. Overexpression of the *yaaDE* operon with a strong constitutive promoter or the deregulation of the expression of the *yaaD* or *yaaE* gene(s) leads to significantly increased production of B6 vitamers. These quantities are significantly higher relative to the associated parent strains than those reported in previous studies, which have  
5 employed mutant *E. coli* strains (Dempsey and Arcement (1971) *J. Bacteriol.* 107 (2): 580-582), or mutant *B. subtilis* strains (Pflug, W., and Lingens, F., (1978) Hoppe-Seyler's *Z. Physiol. Chem.* 359: 559-570).

Accordingly, the present invention features organisms that have been genetically modified to increase the activity of one or more enzymes that catalyze a step  
10 in the biosynthesis of a B6 vitamer, such that B6 vitamer production from the modified organism is increased compared to B6 production in an unmodified parent organism. In one embodiment, B6 vitamer production is at least ten-fold higher than from the unmodified parent organism. In another embodiment, the organism is genetically modified to overexpress one or more genes that encodes an enzyme that catalyzes a step  
15 in the biosynthesis of a B6 vitamer, *e.g.*, *yaaD* or *yaaE*. The organism may be, for example, *B. subtilis*.

The present invention also features methods of producing a B6 vitamer comprising culturing a microorganism that has been genetically modified to overexpress one or more genes that encodes an enzyme that catalyzes a step in the biosynthesis of a  
20 B6 vitamer, such that B6 vitamer production from said modified organism is increased compared to B6 production in an unmodified parent organism, under conditions such that the B6 vitamer is produced. The B6 vitamer may then be subsequently recovered. Overproduction of the rate limiting enzyme for B6 vitamer production in any organism that is capable of producing B6 vitamers will lead to overproduction of B6 vitamers.

The terms "B6 vitamer" or "B6 vitamers," as used herein, shall refer to any compound or mixture of compounds that has any biological activity in any biological assay for vitamin B6. B6 vitamers include, but are not limited to, pyridoxine (also called pyridoxol or PN), pyridoxal (PL), pyridoxamine (PM), the 5' phosphorylated derivatives of any of the three aforementioned compounds (PNP, PLP, and PMP), and any derivative or related compound that can be converted to the active forms (PLP or PMP) in a test organism. Thus, for example, the acetate esters or other  
30 esters of any of the available hydroxyl groups of any of the aforementioned six compounds, and which are likely to be hydrolyzed by specific or non-specific esterases, are included in B6 vitamers. Also, various salts, such as hydrochloride salts, of any of  
35 the aforementioned compounds are included in B6 vitamers.

The term "B6 vitamer biosynthetic pathway" includes the biosynthetic pathway involving B6 vitamer biosynthetic enzymes (*e.g.*, polypeptides encoded by

60367863-032503



biosynthetic enzyme-encoding genes), compounds (*e.g.*, precursors, substrates, intermediates or products), cofactors and the like utilized in the formation or synthesis of B6 vitamers. The term "B6 vitamer biosynthetic pathway" includes the biosynthetic pathway leading to the synthesis of B6 vitamers in a microorganism (*e.g.*, *in vivo*) as well as the biosynthetic pathway leading to the synthesis of B6 vitamers *in vitro*.

A "biological assay for a B6 vitamer" includes, for example, any assay that is capable of quantifying B6 vitamer activity by measuring growth of an organism that requires the feeding of a B6 vitamer (*i.e.*, a compound that the fed organism can convert into PLP or PMP) for growth. Samples to be assayed are diluted serially in an appropriate medium and fed to the appropriate organism. Standard curves are generated by serially diluting known amounts of PL, PN, or PM, and feeding these dilutions to the test organism. By comparing dilutions of the unknown samples to the standard curves, total B6 vitamer activity can be determined, for example as PL equivalents if PL was used to generate the standard curve.

Various aspects of the invention are described in further detail in the following subsections.

I. Genes Encoding Various B6 Vitamer Biosynthetic Enzymes

In one embodiment, the present invention features targeting or modifying various biosynthetic genes or enzymes of the B6 vitamer biosynthetic pathway. In particular, the invention features modifying various enzymatic activities associated with said pathways by modifying or altering the genes encoding said biosynthetic enzymes.

The term "gene", as used herein, includes a nucleic acid molecule (*e.g.*, a DNA molecule or segment thereof) that, in an organism, can be separated from another gene or other genes, by intergenic DNA (*i.e.*, intervening or spacer DNA which naturally flanks the gene and/or separates genes in the chromosomal DNA of the organism). Alternatively, a gene may slightly overlap another gene (*e.g.*, the 3' end of a first gene overlapping the 5' end of a second gene), said overlapping genes separated from other genes by intergenic DNA. A gene may direct synthesis of an enzyme or other protein molecule (*e.g.*, may comprise coding sequences, for example, a contiguous open reading frame (ORF) which encodes a protein) or may itself be functional in the organism. A gene in an organism, may be clustered in an operon, as defined herein, said operon being separated from other genes and/or operons by the intergenic DNA. An "isolated gene", as used herein, includes a gene which is essentially free of sequences which naturally flank the gene in the chromosomal DNA of the organism from which the gene is derived (*i.e.*, is free of adjacent coding sequences which encode a second or

150367863.032502

distinct protein, adjacent structural sequences or the like) and optionally includes 5' and 3' regulatory sequences, for example promoter sequences and/or terminator sequences. In one embodiment, an isolated gene includes predominantly coding sequences for a protein (e.g., sequences which encode *Bacillus* proteins). In another embodiment, an isolated gene includes coding sequences for a protein (e.g., for a *Bacillus* protein) and adjacent 5' and/or 3' regulatory sequences from the chromosomal DNA of the organism from which the gene is derived (e.g., adjacent 5' and/or 3' *Bacillus* regulatory sequences). Preferably, an isolated gene contains less than about 10 kb, 5 kb, 2 kb, 1 kb, 0.5 kb, 0.2 kb, 0.1 kb, 50 bp, 25 bp or 10 bp of nucleotide sequences that naturally flank the gene in the chromosomal DNA of the organism from which the gene is derived.

The term "operon" includes at least two adjacent genes or ORFs, optionally overlapping in sequence at either the 5' or 3' end of at least one gene or ORF. The term "operon" includes a coordinated unit of gene expression that contains a promoter and possibly a regulatory element associated with one or more adjacent genes or ORFs (e.g., structural genes encoding enzymes, for example, biosynthetic enzymes). Expression of the genes (e.g., structural genes) can be coordinately regulated, for example, by regulatory proteins binding to the regulatory element or by anti-termination of transcription. The genes of an operon (e.g., structural genes) can be transcribed to give a single mRNA that encodes all of the proteins.

A "gene having a mutation" or "mutant gene" as used herein, includes a gene having a nucleotide sequence which includes at least one alteration (e.g., substitution, insertion, deletion) such that the polypeptide or protein encoded by said mutant exhibits an activity that differs from the polypeptide or protein encoded by the wild-type nucleic acid molecule or gene. In one embodiment, a gene having a mutation or mutant gene encodes a polypeptide or protein having an increased activity as compared to the polypeptide or protein encoded by the wild-type gene, for example, when assayed under similar conditions (e.g., assayed in microorganisms cultured at the same temperature). As used herein, an "increased activity" or "increased enzymatic activity" is one that is at least 5% greater than that of the polypeptide or protein encoded by the wild-type nucleic acid molecule or gene, preferably at least 5-10% greater, more preferably at least 10-25% greater and even more preferably at least 25-50%, 50-75% or 75-100% greater than that of the polypeptide or protein encoded by the wild-type nucleic acid molecule or gene. Ranges intermediate to the above-recited values, e.g., 75-85%, 85-90%, 90-95%, are also intended to be encompassed by the present invention. As used herein, an "increased activity" or "increased enzymatic activity" can also include an activity that is at least 1.25-fold greater than the activity of the polypeptide or protein encoded by the wild-type gene, preferably at least 1.5-fold

60367663.032502

greater, more preferably at least 2-fold greater and even more preferably at least 3-fold, 4-fold, 5-fold, 10-fold, 20-fold, 50-fold, 100-fold or greater than the activity of the polypeptide or protein encoded by the wild-type gene.

In another embodiment, a gene having a mutation or mutant gene  
5 encodes a polypeptide or protein having a reduced activity as compared to the polypeptide or protein encoded by the wild-type gene, for example, when assayed under similar conditions (*e.g.*, assayed in microorganisms cultured at the same temperature). A mutant gene also can encode no polypeptide or have a reduced level of production of the wild-type polypeptide. As used herein, a "reduced activity" or "reduced enzymatic  
10 activity" is one that is at least 5% less than that of the polypeptide or protein encoded by the wild-type nucleic acid molecule or gene, preferably at least 5-10% less, more preferably at least 10-25% less and even more preferably at least 25-50%, 50-75% or 75-100% less than that of the polypeptide or protein encoded by the wild-type nucleic acid molecule or gene. Ranges intermediate to the above-recited values, *e.g.*, 75-85%,  
15 85-90%, 90-95%, are also intended to be encompassed by the present invention. As used herein, a "reduced activity" or "reduced enzymatic activity" can also include an activity that has been deleted or "knocked out" (*e.g.*, approximately 100% less activity than that of the polypeptide or protein encoded by the wild-type nucleic acid molecule or gene).

20 Activity can be determined according to any well accepted assay for measuring activity of a particular protein of interest. Activity can be measured or assayed directly, for example, measuring an enzymatic or biological activity of a protein isolated or purified from a cell or microorganism. Alternatively, an activity can be measured or assayed within a cell or microorganism or in an extracellular medium. For  
25 example, assaying for a mutant gene (*i.e.*, said mutant encoding a reduced enzymatic activity) can be accomplished by expressing the mutated gene in a microorganism, for example, a mutant microorganism in which the enzyme is temperature-sensitive, and assaying the mutant gene for the ability to complement a temperature sensitive (Ts) mutant for enzymatic activity. A mutant gene that encodes an "increased enzymatic  
30 activity" can be one that complements the Ts mutant more effectively than, for example, a corresponding wild-type gene. A mutant gene that encodes a "reduced enzymatic activity" is one that complements the Ts mutant less effectively than, for example, a corresponding wild-type gene.

It will be appreciated by the skilled artisan that even a single substitution  
35 in a nucleic acid or gene sequence (*e.g.*, a base substitution that encodes an amino acid change in the corresponding amino acid sequence) can dramatically affect the activity of an encoded polypeptide or protein as compared to the corresponding wild-type

603678153-032502

polypeptide or protein. A mutant gene (e.g., encoding a mutant polypeptide or protein), as defined herein, is readily distinguishable from a nucleic acid or gene encoding a protein homologue in that a mutant gene encodes a protein or polypeptide having an altered activity, optionally observable as a different or distinct phenotype in a

5 microorganism expressing said mutant gene or producing said mutant protein or polypeptide (i.e., a mutant microorganism) as compared to a corresponding microorganism expressing the wild-type gene. By contrast, a protein homologue has an identical or substantially similar activity, optionally phenotypically indiscernible when produced in a microorganism, as compared to a corresponding microorganism

10 expressing the wild-type gene. Accordingly it is not, for example, the degree of sequence identity between nucleic acid molecules, genes, protein or polypeptides that serves to distinguish between homologues and mutants, rather it is the activity of the encoded protein or polypeptide that distinguishes between homologues and mutants: homologues having, for example, low (e.g., 30-50% sequence identity) sequence

15 identity yet having substantially equivalent functional activities, and mutants, for example sharing 99% sequence identity yet having dramatically different or altered functional activities.

In a preferred embodiment, the genes of the present invention are derived from *Bacillus*. The term "derived from *Bacillus*" or "*Bacillus*-derived" includes a gene

20 which is naturally found in microorganisms of the genus *Bacillus*. In another preferred embodiment, the genes of the present invention are derived from a microorganism selected from the group consisting of *Bacillus subtilis*, *Bacillus lentimorbus*, *Bacillus lentus*, *Bacillus firmus*, *Bacillus pantothenicus*, *Bacillus amyloliquefaciens*, *Bacillus cereus*, *Bacillus circulans*, *Bacillus coagulans*, *Bacillus licheniformis*, *Bacillus megaterium*, *Bacillus pumilus*, *Bacillus thuringiensis*, *Bacillus halodurans*, and other

25 Group 1 *Bacillus* species, for example, as characterized by 16S rRNA type. In another preferred embodiment, the gene is derived from *Bacillus brevis* or *Bacillus stearothermophilus*. In another preferred embodiment, the genes of the present invention are derived from a microorganism selected from the group consisting of

30 *Bacillus licheniformis*, *Bacillus amyloliquefaciens*, *Bacillus subtilis*, and *Bacillus pumilus*. In a particularly preferred embodiment, the gene is derived from *Bacillus subtilis* (e.g., is *Bacillus subtilis*-derived). The term "derived from *Bacillus subtilis*" or "*Bacillus subtilis*-derived" includes a gene which is naturally found in the microorganism *Bacillus subtilis*. Included within the scope of the present invention are

35 *Bacillus*-derived genes (e.g., *B. subtilis*-derived genes), for example, *Bacillus* or *B. subtilis yaaD* or *yaaE* genes.

60367863-032502

## II. Recombinant Nucleic Acid Molecules and Vectors

60367963-032502

The present invention further features recombinant nucleic acid molecules (e.g., recombinant DNA molecules) that include genes described herein (e.g., isolated genes), preferably *Bacillus* genes, more preferably *Bacillus subtilis* genes, even more preferably *Bacillus subtilis* B6 vitamers biosynthetic genes. The term "recombinant nucleic acid molecule" includes an isolated nucleic acid molecule (e.g., a DNA molecule) that has been altered, modified or engineered such that it differs in nucleotide sequence from the native or natural nucleic acid molecule from which the recombinant nucleic acid molecule was derived (e.g., by addition, deletion or substitution of one or more nucleotides). Preferably, a recombinant nucleic acid molecule (e.g., a recombinant DNA molecule) includes an isolated gene of the present invention operably linked to regulatory sequences. The phrase "operably linked to regulatory sequence(s)" means that the nucleotide sequence of the gene of interest is linked to the regulatory sequence(s) in a manner which allows for expression (e.g., enhanced, increased, constitutive, basal, attenuated, decreased or repressed expression) of the gene, preferably expression of a gene product encoded by the gene (e.g., when the recombinant nucleic acid molecule is included in a recombinant vector, as defined herein, and is introduced into a microorganism). A "recombinant organism" is any organism that contains a recombinant nucleic acid molecule.

The term "regulatory sequence" includes nucleic acid sequences that affect (e.g., modulate or regulate) expression of other nucleic acid sequences (i.e., genes). In one embodiment, a regulatory sequence is included in a recombinant nucleic acid molecule in a similar or identical position and/or orientation relative to a particular gene of interest as is observed for the regulatory sequence and gene of interest as it appears in nature, e.g., in a native position and/or orientation. For example, a gene of interest can be included in a recombinant nucleic acid molecule operably linked to a regulatory sequence which accompanies or is adjacent to the gene of interest in the natural organism (e.g., operably linked to "native" regulatory sequences (e.g., to the "native" promoter). Alternatively, a gene of interest can be included in a recombinant nucleic acid molecule operably linked to a regulatory sequence which accompanies or is adjacent to another (e.g., a different) gene in the natural organism. Alternatively, a gene of interest can be included in a recombinant nucleic acid molecule operably linked to a regulatory sequence from another organism. For example, regulatory sequences from other microbes (e.g., other bacterial regulatory sequences, bacteriophage regulatory sequences and the like) can be operably linked to a particular gene of interest.

In one embodiment, a regulatory sequence is a non-native or non-naturally-occurring sequence (e.g., a sequence which has been modified, mutated,

E0367863-032502

substituted, derivatized, deleted including sequences which are chemically synthesized). Preferred regulatory sequences include promoters, enhancers, termination signals, anti-termination signals, ribosome binding sites and other expression control elements (*e.g.*, sequences to which repressors or inducers bind and/or binding sites for transcriptional and/or translational regulatory proteins, for example, in the transcribed mRNA). Such regulatory sequences are described, for example, in Sambrook, J., Fritsh, E. F., and Maniatis, T. *Molecular Cloning: A Laboratory Manual*. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989. Regulatory sequences include those which direct constitutive expression of a nucleotide sequence in a microorganism (*e.g.*, constitutive promoters and strong constitutive promoters), those which direct inducible expression of a nucleotide sequence in a microorganism (*e.g.*, inducible promoters, for example, xylose inducible promoters) and those which attenuate or repress expression of a nucleotide sequence in a microorganism (*e.g.*, attenuation signals or repressor sequences). It is also within the scope of the present invention to regulate expression of a gene of interest by removing or deleting regulatory sequences. For example, sequences involved in the negative regulation of transcription can be removed such that expression of a gene of interest is enhanced.

In one embodiment, a recombinant nucleic acid molecule of the present invention includes a nucleic acid sequence or gene that encodes at least one bacterial gene product (*e.g.*, a B6 vitamers biosynthetic enzyme, *e.g.*, the gene product of *yaaD* and/or *yaaE*) operably linked to a promoter or promoter sequence. Preferred promoters of the present invention include *Bacillus* promoters and/or bacteriophage promoters (*e.g.*, bacteriophage which infect *Bacillus*). In one embodiment, a promoter is a *Bacillus* promoter, preferably a strong *Bacillus* promoter (*e.g.*, a promoter associated with a biochemical housekeeping gene in *Bacillus* or a promoter associated with a glycolytic pathway gene in *Bacillus*). In another embodiment, a promoter is a bacteriophage promoter. In a preferred embodiment, the promoter is from the bacteriophage SP01. In a particularly preferred embodiment, a promoter is selected from the group consisting of  $P_{15}$ ,  $P_{26}$ , or  $P_{veg}$  having for example, the following respective sequences:

GCTATTGACGACAGCTATGGTTCAGTGTCCACCAACCAAACTGTGCTCAGT  
ACGCCAATATTTCTCCCTTGAGGGGTACAAAGAGGTGTCCCTAGAAGAGAT  
CCACGCTGTGTAAAAATTTTACAAAAAGGTATTGACTTTCCTACAGGGTGT  
GTAATAATTTAATTACAGGCGGGGGCAACCCGCCTGT (SEQ ID NO:9),  
GCCTACCTAGCTTCCAAGAAAGATATCCTAACAGCACAAGAGCGGAAAGAT  
GTTTGTCTACATCCAGAACAACCTCTGTAAAATTCCTGAAAAATTTTGC  
AAAAAGTTGTTGACTTTATCTACAAGGTGTGGTATAATAATCTTAACAACAG  
CAGGACGC (SEQ ID NO:10); and

GAGGAATCATAGAATTTTGTCAAAATAATTTTATTGACAACGTCTTATTAAC  
 GTTGATATAATTTAAATTTTATTGACAAAAATGGGCTCGTGTGTACAATA  
 AATGTAGTGAGGTGGATGCAATG (SEQ ID NO:11). Additional preferred  
 promoters include *tef* (the translational elongation factor (TEF) promoter) and *pyc* (the  
 5 pyruvate carboxylase (PYC) promoter), which promote high level expression in *Bacillus*  
 (*e.g.*, *Bacillus subtilis*). Additional preferred promoters, for example, for use in Gram  
 positive microorganisms include, but are not limited to, *amy* and SPO2 promoters.  
 Additional preferred promoters, for example, for use in Gram negative microorganisms  
 include, but are not limited to, *tac*, *trp*, *tet*, *trp-tet*, *lpp*, *lac*, *lpp-lac*, *lacIQ*, T7, T5, T3,  
 10 *gal*, *trc*, *ara*, SP6,  $\lambda$ -PR or  $\lambda$ -PL.

In another embodiment, a recombinant nucleic acid molecule of the  
 present invention includes a terminator sequence or terminator sequences (*e.g.*,  
 transcription terminator sequences). The term "terminator sequences" includes  
 regulatory sequences that serve to terminate transcription of mRNA. Terminator  
 15 sequences (or tandem transcription terminators) can further serve to stabilize mRNA  
 (*e.g.*, by adding structure to mRNA), for example, against nucleases.

In yet another embodiment, a recombinant nucleic acid molecule of the  
 present invention includes sequences which allow for detection of the vector containing  
 said sequences (*i.e.*, detectable and/or selectable markers), for example, genes that  
 20 encode antibiotic resistance or sequences that overcome auxotrophic mutations, for  
 example, *trpC*, fluorescent markers, drug markers, and/or colorimetric markers (*e.g.*,  
*lacZ*/ $\beta$ -galactosidase). In yet another embodiment, a recombinant nucleic acid molecule  
 of the present invention includes an artificial ribosome binding site (RBS) or a sequence  
 that becomes transcribed into an artificial RBS. The term "artificial ribosome binding  
 25 site (RBS)" includes a site within an mRNA molecule (*e.g.*, coded within DNA) to  
 which a ribosome binds (*e.g.*, to initiate translation) which differs from a native RBS  
 (*e.g.*, a RBS found in a naturally-occurring gene) by at least one nucleotide. Preferred  
 artificial RBSs include about 5-6, 7-8, 9-10, 11-12, 13-14, 15-16, 17-18, 19-20, 21-22,  
 23-24, 25-26, 27-28, 29-30 or more nucleotides of which about 1-2, 3-4, 5-6, 7-8, 9-10,  
 30 11-12, 13-15 or more differ from the native RBS (*e.g.*, the native RBS of a gene of  
 interest, for example, the native *yaaD* RBS

GAAATCATATAACTATACCTTGATTAGGGGGACCAAGAAATG

(SEQ ID NO:12) or the native *yaaE* RBS

CAAGAACGCGGCTGGTAAGAACATAGGAGCGCTGCTGACATG (SEQ ID  
 35 NO:13)).


Preferably, nucleotides that differ are substituted such that they are  
 identical to one or more nucleotides of an ideal RBS when optimally aligned for

50367863.032502

comparisons. Artificial RBSs can be used to replace the naturally-occurring or native RBSs associated with a particular gene. Artificial RBSs preferably increase translation of a particular gene. Preferred artificial RBSs (*e.g.*, RBSs for increasing the translation of *yaaE*, for example, of *B. subtilis*) are set forth in Table 1, below.

5

**Table 1: Preferred Ribosome Binding Sites**

	10	20	
10			SEQ ID NO:
	Native_yaaD	---GAAATCATATAACTATACCTTGATTAGGGGGACC-AAGAAATG	12
	Native_yaaE	CAAGAACGCGGCTGGTAAGAACAT----AGGAGCGCTGCTGACATG	13
	IDEAL_RBS	-----TCTAGAAAGG----AGGTG-----A-----	14
	RBS1	-----TCTAGAAGG----AGGAG-----AAAACATG	15
15	RBS2	-----TCTAGAGG----AGGAG-----AAAACATG	16
	RBS101	-----TAAGAACAA---AGGAGGAGAGCTGACATG	17
	RBS103	-----TAAGAAGAA---AGGAGGTGAGCTGACATG	18
	RBS102	-----TAAGAACAG---AGGAGGAGAGCTGACATG	19

20

The present invention further features vectors (*e.g.*, recombinant vectors) that include nucleic acid molecules (*e.g.*, genes or recombinant nucleic acid molecules comprising said genes) as described herein. The term "recombinant vector" includes a vector (*e.g.*, plasmid, phage, phasmid, virus, cosmid or other purified nucleic acid vector) that has been altered, modified or engineered such that it contains greater, fewer or different nucleic acid sequences than those included in the native or natural nucleic acid molecule from which the recombinant vector was derived. Preferably, the recombinant vector includes a biosynthetic enzyme-encoding gene or recombinant nucleic acid molecule including said gene, operably linked to regulatory sequences, for example, promoter sequences, terminator sequences and/or artificial ribosome binding sites (RBSs), as defined herein. In another embodiment, a recombinant vector of the present invention includes sequences that enhance replication in bacteria (*e.g.*, replication-enhancing sequences). In one embodiment, replication-enhancing sequences are derived from *E. coli*. In another embodiment, replication-enhancing sequences are derived from pBR322. In another embodiment, replication-enhancing sequences are derived from pSC101.

35

In yet another embodiment, a recombinant vector of the present invention includes antibiotic resistance sequences. The term "antibiotic resistance sequences" includes sequences which promote or confer resistance to antibiotics on the host organism (*e.g.*, *Bacillus*). In one embodiment, the antibiotic resistance sequences are selected from the group consisting of *cat* (chloramphenicol resistance) sequences, *tet* (tetracycline resistance) sequences, *erm* (erythromycin resistance) sequences, *neo*

40

60367863.032502



(neomycin resistance) sequences, *kan* (kanamycin resistance) and *spec* (spectinomycin resistance) sequences. Recombinant vectors of the present invention can further include homologous recombination sequences (e.g., sequences designed to allow recombination of the gene of interest into the chromosome of the host organism). For example, *bpr*, *vpr*, and/or *amyE* sequences can be used as homology targets for recombination into the host chromosome. It will further be appreciated by one of skill in the art that the design of a vector can be tailored depending on such factors as the choice of microorganism to be genetically engineered, the level of expression of gene product desired and the like.

### III. Recombinant Microorganisms

The present invention further features microorganisms, i.e., recombinant microorganisms, that include vectors or genes (e.g., wild-type and/or mutated genes) as described herein. As used herein, the term "recombinant microorganism" includes a microorganism (e.g., bacteria, yeast cell, fungal cell, etc.) that has been genetically altered, modified or engineered (e.g., genetically engineered) such that it exhibits an altered, modified or different genotype and/or phenotype (e.g., when the genetic modification affects coding nucleic acid sequences of the microorganism) as compared to the naturally-occurring microorganism from which it was derived.

In one embodiment, a recombinant microorganism of the present invention is a Gram positive organism (e.g., a microorganism which retains basic dye, for example, crystal violet, due to the presence of a Gram-positive wall surrounding the microorganism). In a preferred embodiment, the recombinant microorganism is a microorganism belonging to a genus selected from the group consisting of *Bacillus*, *Corynebacterium*, *Lactobacillus*, *Lactococci* and *Streptomyces*. In a more preferred embodiment, the recombinant microorganism is of the genus *Bacillus*. In another preferred embodiment, the recombinant microorganism is selected from the group consisting of *Bacillus subtilis*, *Bacillus lentimorbus*, *Bacillus lentus*, *Bacillus firmus*, *Bacillus pantothenicus*, *Bacillus amyloliquefaciens*, *Bacillus cereus*, *Bacillus circulans*, *Bacillus coagulans*, *Bacillus licheniformis*, *Bacillus megaterium*, *Bacillus pumilus*, *Bacillus thuringiensis*, *Bacillus halodurans*, and other Group 1 *Bacillus* species, for example, as characterized by 16S rRNA type. In another preferred embodiment, the recombinant microorganism is *Bacillus brevis* or *Bacillus stearothermophilus*. In another preferred embodiment, the recombinant microorganism is selected from the group consisting of *Bacillus licheniformis*, *Bacillus amyloliquefaciens*, *Bacillus subtilis*, and *Bacillus pumilus*.

In another embodiment, the recombinant microorganism is a Gram negative (excludes basic dye) organism. In a preferred embodiment, the recombinant

60367883-032502

microorganism is a microorganism belonging to a genus selected from the group consisting of *Salmonella*, *Escherichia*, *Klebsiella*, *Serratia*, and *Proteus*. In a more preferred embodiment, the recombinant microorganism is of the genus *Escherichia*. In an even more preferred embodiment, the recombinant microorganism is *Escherichia coli*. In another embodiment, the recombinant microorganism is *Saccharomyces* (e.g., *S. cerevisiae*).

A preferred "recombinant" microorganism of the present invention is a microorganism having a deregulated B6 vitamer biosynthesis pathway or enzyme. The term "deregulated" or "deregulation" includes the alteration or modification of at least one gene in a microorganism that encodes an enzyme in a biosynthetic pathway, such that the level or activity of the biosynthetic enzyme in the microorganism is altered or modified. Preferably, at least one gene that encodes an enzyme in a biosynthetic pathway is altered or modified such that the gene product is enhanced or increased. The phrase "deregulated pathway" can also include a biosynthetic pathway in which more than one gene that encodes an enzyme in a biosynthetic pathway is altered or modified such that the level or activity of more than one biosynthetic enzyme is altered or modified. The ability to "deregulate" a pathway (e.g., to simultaneously deregulate more than one gene in a given biosynthetic pathway) in a microorganism in some cases arises from the particular phenomenon of microorganisms in which more than one enzyme (e.g., two or three biosynthetic enzymes) are encoded by genes occurring adjacent to one another on a contiguous piece of genetic material termed an "operon" (defined herein). Due to the coordinated regulation of genes included in an operon, alteration or modification of the single promoter and/or regulatory element can result in alteration or modification of the expression of more than one gene product encoded by the operon. Alteration or modification of the regulatory element can include, but is not limited to removing the endogenous promoter and/or regulatory element(s), adding strong promoters, inducible promoters or multiple promoters or removing regulatory sequences such that expression of the gene products is modified, modifying the chromosomal location of the operon, altering nucleic acid sequences adjacent to the operon or within the operon such as a ribosome binding site, increasing the copy number of the operon, modifying proteins (e.g., regulatory proteins, suppressors, enhancers, transcriptional activators and the like) involved in transcription of the operon and/or translation of the gene products of the operon, or any other conventional means of deregulating expression of genes routine in the art (including but not limited to use of antisense nucleic acid molecules, for example, to block expression of repressor proteins). Deregulation can also involve altering the coding region of one or more genes

50367863-032502

to yield, for example, an enzyme that is feedback resistant or has a higher or lower specific activity.

In another preferred embodiment, a recombinant microorganism is designed or engineered such that at least one B6 vitamers biosynthetic enzyme, is overexpressed. The term "overexpressed" or "overexpression" includes expression of a gene product (e.g., a biosynthetic enzyme) at a level greater than that expressed prior to manipulation of the microorganism or in a comparable microorganism which has not been manipulated. In one embodiment, the microorganism can be genetically designed or engineered to overexpress a level of gene product greater than that expressed in a comparable microorganism which has not been engineered.

Genetic engineering can include, but is not limited to, altering or modifying regulatory sequences or sites associated with expression of a particular gene (e.g., by adding strong promoters, inducible promoters or multiple promoters or by removing regulatory sequences such that expression is constitutive), modifying the chromosomal location of a particular gene, altering nucleic acid sequences adjacent to a particular gene such as a ribosome binding site, increasing the copy number of a particular gene, modifying proteins (e.g., regulatory proteins, suppressors, enhancers, transcriptional activators and the like) involved in transcription of a particular gene and/or translation of a particular gene product, or any other conventional means of deregulating expression of a particular gene routine in the art (including but not limited to use of antisense nucleic acid molecules, for example, to block expression of repressor proteins). Genetic engineering can also include deletion of a gene, for example, to block a pathway or to remove a repressor. In embodiments featuring microorganisms having deleted genes, the skilled artisan will appreciate that at least low levels of certain compounds may be required to be present in or added to the culture medium in order that the viability of the microorganism is not compromised. Often, such low levels are present in complex culture media as routinely formulated. Moreover, in processes featuring culturing microorganisms having deleted genes cultured under conditions such that commercially or industrially attractive quantities of product are produced, it may be necessary to supplement culture media with slightly increased levels of certain compounds.

In another embodiment, the microorganism can be physically or environmentally manipulated to overexpress a level of gene product greater than that expressed prior to manipulation of the microorganism or in a comparable microorganism which has not been manipulated. For example, a microorganism can be treated with or cultured in the presence of an agent known or suspected to increase transcription of a particular gene and/or translation of a particular gene product such that transcription

0367863-032502

and/or translation are enhanced or increased. Alternatively, a microorganism can be cultured at a temperature selected to increase transcription of a particular gene and/or translation of a particular gene product such that transcription and/or translation are enhanced or increased.

5

#### IV. Culturing and Fermenting Recombinant Microorganisms

The term "culturing" includes maintaining and/or growing a living microorganism of the present invention (e.g., maintaining and/or growing a culture or strain). In one embodiment, a microorganism of the invention is cultured in liquid media. In another embodiment, a microorganism of the invention is cultured in solid media or semi-solid media. In a preferred embodiment, a microorganism of the invention is cultured in media (e.g., a sterile, liquid media) comprising nutrients essential or beneficial to the maintenance and/or growth of the microorganism (e.g., carbon sources or carbon substrate, for example carbohydrate, hydrocarbons, oils, fats, fatty acids, organic acids, and alcohols; nitrogen sources, for example, peptone, yeast extracts, meat extracts, malt extracts, soy flour, urea, ammonium sulfate, ammonium chloride, ammonium nitrate and ammonium phosphate; phosphorus sources, for example, phosphoric acid, sodium and potassium salts thereof; trace elements, for example, magnesium, iron, manganese, calcium, copper, zinc, boron, molybdenum, and/or cobalt salts; as well as growth factors such as amino acids, vitamins, and the like).

Preferably, microorganisms of the present invention are cultured under controlled pH. The term "controlled pH" includes any pH which results in production of the desired product. In one embodiment microorganisms are cultured at a pH of about 7. In another embodiment, microorganisms are cultured at a pH of between 6.0 and 8.5. The desired pH may be maintained by any number of methods known to those skilled in the art.

Also preferably, microorganisms of the present invention are cultured under controlled aeration. The term "controlled aeration" includes sufficient aeration (e.g., oxygen) to result in production of the desired product. In one embodiment, aeration is controlled by regulating oxygen levels in the culture, for example, by regulating the amount of oxygen dissolved in culture media. Preferably, aeration of the culture is controlled by agitating the culture. Agitation may be provided by a propeller or similar mechanical agitation equipment, by revolving or shaking the culture vessel (e.g., tube or flask) or by various pumping equipment. Aeration may be further controlled by the passage of sterile air or oxygen through the medium (e.g., through the

fermentation mixture). Also preferably, microorganisms of the present invention are cultured without excess foaming (*e.g.*, *via* addition of antifoaming agents).

Moreover, microorganisms of the present invention can be cultured under controlled temperatures. The term "controlled temperature" includes any temperature which results in production of the desired product (*e.g.*, a B6 vitamer). In one embodiment, controlled temperatures include temperatures between 15°C and 95°C. In another embodiment, controlled temperatures include temperatures between 15°C and 70°C. Preferred temperatures are between 20°C and 55°C, more preferably between 30°C and 50°C.

Microorganisms can be cultured (*e.g.*, maintained and/or grown) in liquid media and preferably are cultured, either continuously or intermittently, by conventional culturing methods such as standing culture, test tube culture, shaking culture (*e.g.*, rotary shaking culture, shake flask culture, etc.), aeration spinner culture, or fermentation. In a preferred embodiment, the microorganisms are cultured in shake flasks. In a more preferred embodiment, the microorganisms are cultured in a fermentor (*e.g.*, a fermentation process). Fermentation processes of the present invention include, but are not limited to, batch, fed-batch and continuous processes or methods of fermentation. The phrase "batch process" or "batch fermentation" refers to a closed system in which the composition of media, nutrients, supplemental additives and the like is set at the beginning of the fermentation and not subject to alteration during the fermentation, however, attempts may be made to control such factors as pH and oxygen concentration to prevent excess media acidification and/or microorganism death. The phrase "fed-batch process" or "fed-batch" fermentation refers to a batch fermentation with the exception that one or more substrates or supplements are added (*e.g.*, added in increments or continuously) as the fermentation progresses. The phrase "continuous process" or "continuous fermentation" refers to a system in which a defined fermentation media is added continuously to a fermentor and an equal amount of used or "conditioned" media is simultaneously removed, preferably for recovery of the desired product (*e.g.*, a B6 vitamer). A variety of such processes have been developed and are well-known in the art.

The phrase "culturing under conditions such that a desired compound is produced" includes maintaining and/or growing microorganisms under conditions (*e.g.*, temperature, pressure, pH, duration, etc.) appropriate or sufficient to obtain production of the desired compound or to obtain desired yields of the particular compound being produced. For example, culturing is continued for a time sufficient to produce the desired amount of a compound (*e.g.*, a B6 vitamer). Preferably, culturing is continued for a time sufficient to substantially reach suitable production of the compound (*e.g.*, a

60367863-032502

60367863-032502

time sufficient to reach a suitable concentration of a B6 vitamer). In one embodiment, culturing is continued for about 12 to 24 hours. In another embodiment, culturing is continued for about 24 to 36 hours, 36 to 48 hours, 48 to 72 hours, 72 to 96 hours, 96 to 120 hours, 120 to 144 hours, or greater than 144 hours. The methodology of the present invention can further include a step of recovering a desired compound (e.g., a B6 vitamer). The term "recovering" a desired compound includes extracting, harvesting, isolating or purifying the compound from culture media. Recovering the compound can be performed according to any conventional isolation or purification methodology known in the art including, but not limited to, treatment with a conventional resin (e.g., anion or cation exchange resin, non-ionic adsorption resin, etc.), treatment with a conventional adsorbent (e.g., activated charcoal, silicic acid, silica gel, cellulose, alumina, etc.), alteration of pH, solvent extraction (e.g., with a conventional solvent such as an alcohol, ethyl acetate, hexane and the like), dialysis, filtration, concentration, crystallization, recrystallization, pH adjustment, lyophilization and the like. For example, a compound can be recovered from culture media by first removing the microorganisms from the culture. The resulting solutions are then passed through or over a cation exchange resin to remove cations and/or through or over an anion exchange resin to purify or concentrate the desired product. The resulting compound can subsequently be converted to a salt (e.g., a chloride or sulfate salt) by ion exchange.

Preferably, a desired compound of the present invention is "extracted," "isolated" or "purified" such that the resulting preparation is substantially free of other media components (e.g., free of media components and/or fermentation byproducts). The language "substantially free of other media components" includes preparations of the desired compound in which the compound is separated from media components or fermentation byproducts of the culture from which it is produced. In one embodiment, the preparation has greater than about 80% (by dry weight) of the desired compound (e.g., less than about 20% of other media components or fermentation byproducts), more preferably greater than about 90% of the desired compound (e.g., less than about 10% of other media components or fermentation byproducts), still more preferably greater than about 95% of the desired compound (e.g., less than about 5% of other media components or fermentation byproducts), and most preferably greater than about 98-99% desired compound (e.g., less than about 1-2% other media components or fermentation byproducts). When the desired compound has been derivatized to a salt, the compound is preferably further free of chemical contaminants associated with the formation of the salt. When the desired compound has been derivatized to an alcohol, the compound is preferably further free of chemical contaminants associated with the formation of the alcohol.

In an alternative embodiment, the desired compound is not purified from the microorganism, for example, when the microorganism is biologically non-hazardous (*e.g.*, safe). For example, the entire culture (or culture supernatant) can be used as a source of product (*e.g.*, crude product). In one embodiment, the culture (or culture supernatant) is used without modification. In another embodiment, the culture (or culture supernatant) is concentrated. In yet another embodiment, the culture (or culture supernatant) is dried or lyophilized.

Preferably, a production method of the present invention results in production of the desired compound, *e.g.*, a B6 vitamer, at a significantly high yield.

10 The phrase "significantly high yield" includes a level of production or yield which is sufficiently elevated or above what is usual for comparable production methods, for example, which is elevated to a level sufficient for commercial production of the desired product (*e.g.*, production of the product at a commercially feasible cost). In one embodiment, the invention features a production method that includes culturing a

15 recombinant microorganism under conditions such that the desired product (*e.g.*, a B6 vitamer) is produced at a level greater than 5 mg/L. In another embodiment, the invention features a production method that includes culturing a recombinant microorganism under conditions such that the desired product (*e.g.*, a B6 vitamer) is produced at a level greater than 10 mg/L. In another embodiment, the invention features

20 a production method that includes culturing a recombinant microorganism under conditions such that the desired product (*e.g.*, a B6 vitamer) is produced at a level greater than 50 mg/L. In yet another embodiment, the invention features a production method that includes culturing a recombinant microorganism under conditions such that the desired product (*e.g.*, a B6 vitamer) is produced at a level greater than 150 mg/L.

25 Depending on the biosynthetic enzyme or combination of biosynthetic enzymes manipulated, it may be desirable or necessary to provide (*e.g.*, feed) microorganisms of the present invention at least one biosynthetic precursor such that the desired compound or compounds are produced. The term "biosynthetic precursor" or "precursor" includes an agent or compound which, when provided to, brought into

30 contact with, or included in the culture medium of a microorganism, serves to enhance or increase biosynthesis of the desired product. In one embodiment, the biosynthetic precursor or precursor is glutamine. In another embodiment, the biosynthetic precursor or precursor is ribose. The amount of glutamine or ribose added is preferably an amount that results in a concentration in the culture medium sufficient to enhance productivity

35 of the microorganism (*e.g.*, a concentration sufficient to enhance production of a B6 vitamer). The term "excess ribose or glutamine" includes ribose or glutamine levels increased or higher than those routinely utilized for culturing the microorganism in

150367463-032502

question. For example, culturing the *Bacillus* microorganisms described in the instant Examples is routinely done in the presence of about 0-5 g/L ribose or glutamine.

Accordingly, excess ribose or glutamine levels can include levels of about 5-10 g/L or more preferably about 5-20 g/L ribose or glutamine. Biosynthetic precursors of the

5 present invention can be added in the form of a concentrated solution or suspension (e.g., in a suitable solvent such as water or buffer) or in the form of a solid (e.g., in the form of a powder). Moreover, biosynthetic precursors of the present invention can be added as a single aliquot, continuously or intermittently over a given period of time.

10

This invention is further illustrated by the following examples which should not be construed as limiting. The contents of all references, patents and published patent applications cited throughout this application are incorporated herein by reference.

15

60367863-032502



## EXAMPLES

**EXAMPLE 1: Biological assay for B6 vitamers using *Saccharomyces uvarum*.**

Quantitation of B6 vitamers in supernatants of cultures of micro-organisms or extracts of organisms that have been genetically modified to increase production of B6 vitamers is conveniently done using *Saccharomyces uvarum* (formerly and still often named *S. carlsbergensis*) strain ATCC 9080 as the indicator strain or test organism. The method is essentially that described in the Difco Manual (1984, Difco Laboratories, Detroit, MI, 10th Edition, pp. 1104-1106), with the modification that 50 mg/liter of streptomycin sulfate is added to the liquid growth medium for the test organism. However, any other appropriate indicator organism may be used, together with a medium that is appropriate for that organism that is free of B6 vitamers. For example, an *E. coli pdxB* mutant can be used in a standard minimal medium that is well known in the art, such as M9 glucose minimal medium (Miller, J., (1972) Experiments in Molecular Genetics, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY).

When using *S. uvarum* strain ATCC 9080 as the indicator strain, Bacto Pyridoxine Y Medium (Difco Laboratories, available through VWR Scientific, Inc.), supplemented with 50 mg/liter streptomycin sulfate, is used for the serial dilutions, and PN, PL, or PM is used to generate the standard curve. The responses to these three standard compounds are almost identical to each other with *S. uvarum* strain ATCC 9080 (Figure 3).

**EXAMPLE 2: Deletion of a portion of the *yaaDE* operon in *B. subtilis*.**

The *SOR* and *SNO* genes of *Cercospora nicotianae* were originally identified by mutations that lead to hypersensitivity to singlet oxygen-generating reagents (Ehrenschaft, M., et al. (1999) *Proc. Natl. Acad. Sci. USA* 96: 9347-9378). Mutations in either of these genes also lead to PL auxotrophy. The protein sequences obtained from translation of the *SOR* and *SNO* open reading frames were used as homology probes to search through the *B. subtilis* genome sequence using the BLAST homology search program of the Subtilist website. The *SOR* protein was significantly homologous to the YaaD protein, and the *SNO* protein was significantly homologous to the YaaE protein. Moreover, the genes encoding the YaaD and YaaE proteins (namely *yaaD* and *yaaE*) occur adjacent to each other on the *B. subtilis* chromosome as a two gene operon.

General methods for growth, storage, transformation, and molecular biology of *B. subtilis* strains are given in Harwood, C., and Cutting, S. (1990), *Molecular Biological Methods for Bacillus*, John Wiley and Sons, New York, NY, hereby

incorporated in its entirety by reference. The *yaaDE* operon DNA sequence was amplified using the Polymerase Chain Reaction (PCR) with Pfu Turbo DNA polymerase (Stratagene, Inc., used according to the manufacturer's instructions). The DNA primers used were RY395 (SEQ ID NO:1) and RY396 (SEQ ID NO:2). RY395, the upstream  
5 primer, introduces an *XbaI* site and artificial ribosome binding site. RY396, the downstream primer, introduces a *BamHI* site. The template DNA was chromosomal DNA isolated from wild type *B. subtilis* strain PY79. The blunt ended PCR product was ligated into the *EcoRV* site of pGEM5Zf(+) (Promega, Inc.) to give plasmid pAN368. Next, a gram positive chloramphenicol resistance gene on a blunt DNA fragment was  
10 ligated into pAN368 that had been cut with *HpaI*, to give plasmid pDX1F (SEQ ID NO:5, Figure 4). pDX1F therefore is deleted for a portion of *yaaD* and a portion of *yaaE*. pDX1F was used to transform wild type *B. subtilis* strain PY79 to 5 mg/liter chloramphenicol resistance, and a double crossover event was confirmed using PCR and the same primers used to clone *yaaDE*. The resulting strain was named PX1.

15 PX1 was able to grow on Spizizen's minimal medium with trace elements (SMM) (Harwood, C., and Cutting, S. (1990) Molecular Biological Methods for *Bacillus*, John Wiley and Sons, New York, NY, pp. 548-549) supplemented with 2  $\mu$ M pyridoxal HCl (Sigma-Aldrich Chemical Co.), but it did not grow without the supplement. Thus it was established that at least one of *yaaD* or *yaaE* is required for  
20 PLP synthesis in *B. subtilis*.

**EXAMPLE 3: Deletion of *yhaF* in *B. subtilis*.**

The protein sequence of the *E. coli* *pdxF* gene was used as a probe to search the *B. subtilis* genome as described in Example 1. The only significant homolog  
25 was *yhaF*. In a fashion similar to that of Example 1, the *yhaF* was cloned and deleted from the chromosome of PY79 using plasmid pDX11F (SEQ ID NO:6, Figure 5), to give strain PX11. The PCR primers used to clone *yhaF* were RY407 (SEQ ID NO:3) and RY408 (SEQ ID NO:4). The restriction sites used for insertion of the antibiotic resistance gene were the *PshAI* and *EheI* sites in the *yhaF* coding region. PX11 is a  
30 serine auxotroph, but not a PL auxotroph. By comparison to *E. coli*, it appears that *yhaF* functions in serine synthesis and probably encodes the equivalent of *SerC*, but that the YhaF protein is not required for PLP synthesis in *B. subtilis*. Therefore, it is established that sequence homology does not necessarily imply functional homology.

35 **EXAMPLE 4: Overexpression of the *yaaDE* operon in *B. subtilis*.**

The *XbaI* to *BamHI* fragment from pAN368 that contains the *yaaDE* operon and artificial ribosome binding site was inserted into either of two expression

60367863-032502

vectors, to yield plasmids pDX14R (SEQ ID NO:7) and pDX17R (SEQ ID NO:8), respectively. In pDX14R and pDX17R, the *yaaDE* operon is expressed from the strong constitutive *B. subtilis* phage SP01 promoters,  $P_{26}$  and  $P_{15}$ , respectively (see Figures 6 and 7).

5 pDX14R and pDX17R were each transformed into wild type *B. subtilis* strain PY79, selecting for chloramphenicol resistance. The plasmids integrate into the chromosome at the *yaaDE* locus by single crossover. The resulting strains were named PX14 and PX17, respectively.

10 PX14 and PX17 were grown for 48 hours at 37°C in 5 ml test tube cultures in a roller drum at about 100 rotations per minute. The culture medium was SVY (20 g Difco Veal Infusion Broth, 5 g Difco Yeast Extract, 2 g ammonium sulfate, 5 g sodium glutamate, and 30 g glucose per liter, buffered with 200 mM potassium phosphate, pH 7.0). Cells were removed by centrifugation followed by sterile filtration (Millipore 0.45 micron), and the supernatant solutions were assayed for PL equivalents using the biological assay described in Example 1. The parent strain, PY79 was grown and processed in similar fashion as a control. The uncultured SVY medium was assayed as another control, since it was likely that the SVY medium contained a measurable level of B6 vitamers. The results are shown in Table 2, below.

20 **Table 2: Production of B6 vitamers by *Bacillus subtilis* derivatives in 48 hour test tube cultures grown in SVY**

Strain	Cassette	Integration Target	OD <sub>600</sub>	Total B6 Vitamers <sup>1</sup> mg/liter	Net B6 Vitamers <sup>2</sup> mg/liter
PX14	$P_{26}yaaDE$	<i>yaaDE</i>	17	7.2	7.0
PX17	$P_{15}yaaDE$	<i>yaaDE</i>	17	4.9	4.7
PX1	$\Delta yaaDE$	<i>yaaDE</i>	8	0.4	0.2
PY79	-	-	19	0.8	0.6
(Medium)	-	-	0.08	0.2	(0)

<sup>1</sup> Sum of PN, PL, PM, and derivatives thereof that can be utilized by pyridoxine indicator strain *S. carlbergensis* as a source of vitamin B6 for growth.

25 <sup>2</sup> Calculated by subtracting the amount assayed in the medium.

After subtracting the B6 vitamers contained in the medium, strain PX14 produced 7.0 mg/liter PL equivalents, while the parent PY79 produced only 0.6 mg/liter of PL equivalents. Thus, expression of the *yaaDE* operon has been shown to be rate limiting for B6 vitamer production in *B. subtilis*. Moreover, a genetically modified

30

B0367863-032502

strain, where this rate limiting step was enhanced, produced more than a ten-fold increase in B6 vitamers secretion compared to that of the parent.

**EXAMPLE 5: Complementation of *E. coli* *pdx* mutants by plasmids that express the *B. subtilis* *yaaDE* operon.**

5 Plasmid pDX14R, described above in Example 4, was used to transform various *E. coli* strains that contained mutations that lacked function in each of the known genes involved in PLP biosynthesis (except for *pdx*, which is an essential gene for *E. coli*). The selection was for resistance to 250 mg/liter ampicillin. Each transformant 10 was then tested for growth on minimal medium (SMM with 0.5 % glucose, see Example 2) supplemented with 100 mg/liter serine, and compared to growth of its respective untransformed parent on the same medium. All mutations tested were complemented by pDX14R. Specifically, *pdxA*, *pdxB*, *pdxF*, *pdxJ*, and *pdxH*, were all complemented by pDX14R. Therefore, expression of the *B. subtilis* *yaaDE* operon in *E. coli* is sufficient 15 for PLP biosynthesis, even in the absence of any one of the above functional *pdx* genes. Several important and unexpected conclusions or inferences can be drawn from these results. First, the substrate(s) for the enzyme(s) encoded by *yaaDE* must be present in *E. coli*, even when a biosynthetic intermediate normally used to make PLP is absent or greatly reduced. Second, PNP or PLP is possibly the product of the enzyme(s) encoded 20 by *yaaDE*. Third, since an early block in the *E. coli* PLP biosynthetic pathway (for example that in a *pdxB* mutant) does not prevent *yaaDE* from complementation, the substrates for the enzyme(s) encoded by *yaaDE* are not likely to be the same as for the last step in PNP or PLP synthesis in wild type *E. coli*. These unexpected results lead to the possibility of producing B6 vitamers using *B. subtilis* *yaaDE* or the homologous 25 genes from another organism (for example, but not limited to, *SOR* and *SNO* from *Cercospora nicotianae* or *PDX1* and *PDX2* from *S. cerevisiae*) in a heterologous host species, including, but not limited to, *E. coli* and *Oryza sativa*.

**EXAMPLE 6: Overexpression of the *yaaDE* operon in *E. coli*.**

30 Plasmids pDX14R and pDX17R were transformed into *E. coli* strain DH5 $\alpha$  (New England Biolabs), selecting for ampicillin resistance. The transformants were grown for 48 hours in 5 ml test tube cultures at 37°C, and the supernatants were worked up as in Example 3. The assay results for PL equivalents are shown in Table 3, below.

35

**Table 3: Production of B6 vitamers by *Escherichia coli* harboring plasmids containing engineered *Bacillus subtilis* genes<sup>1</sup>**

Strain	Plasmid Cassette	OD <sub>600</sub>	Total B6 Vitamers <sup>2</sup> mg/liter	Net B6 Vitamers <sup>3</sup> mg/liter
DH5α	<i>P<sub>26</sub>yaaDE</i>	7.6	3.2	3.1
DH5α	<i>P<sub>15</sub>yaaDE</i>	8.2	3.2	3.1
DH5α	-	9	0.1	(0)

<sup>1</sup>*E. coli* test tube cultures are grown in SVY for 48 hours.

<sup>2</sup>Sum of PN, PL, PM, and derivatives thereof that can be utilized by pyridoxine indicator strain *S. carlbergensis* as a source of vitamin B6 for growth.

<sup>3</sup>Calculated by subtracting the amount assayed in DH5α not containing plasmid.

Thus it has been shown that the *yaaD* and *yaaE* genes can be expressed in a heterologous host strain, and B6 vitamers can still be overproduced. By extension of this approach, the *yaaD* and *yaaE* genes of *B. subtilis* can be overexpressed in any organism where an overexpression system exists, and in the resulting strains, B6 vitamers will be overproduced. Overproduction of the rate limiting enzyme for B6 vitamer production in any organism that is capable of producing B6 vitamers will lead to overproduction of B6 vitamers.

The YaaD and YaaE protein sequences were used as probes to search the NCBI database for homologs in plants using the BLAST™ program which can be found at the National Center for Biotechnology Information website (Altschul S.F (1990) *J. Mol. Biol.* 215(3):403-10). Several homologs of YaaD were found in several genera of plants, including *Arabidopsis*, *Oryza*, *Ginkgo*, *Hevea*, *Phaseolus*, and *Stellaria*. Two homologs of YaaE were found in *Arabidopsis thaliana*. However, no homologs of *pdxA* and *pdxJ* were found. Therefore the plant kingdom appears to use the Type B Pathway for B6 vitamer biosynthesis. Thus for example, overexpression of the YaaD homolog (GenBank accession number AAL73561) from *Oryza sativa* (rice), and the *A. thaliana* homolog of YaaE (GenBank accession number AB011483) together in a plant using methods well know in the art, such as expression from the Cauliflower Mosaic Virus 35S promoter, will lead to overproduction of B6 vitamers in that plant.

**EXAMPLE 7: Other routes to increasing the activity of enzymes involved in B6 vitamer synthesis.**

The overexpression of the *yaaDE* operon leads to an increase in the amount of the encoded enzyme(s), which in turn leads to an increase in the total activity of said enzyme(s). Increase in this activity leads to an increase in the production B6 vitamer. Other methods can be used to increase the activity of the relevant enzyme(s)

60367863-032502  
205250-59879509

under conditions of B6 vitamer production. For example, in addition to increasing the amount of a relevant enzyme(s), the total activity of the relevant enzyme(s) can be increased by mutating the gene(s) to increase the specific activity of the enzyme(s), and/or by mutating the gene(s) to encode a feedback resistant variant of the enzyme(s).

- 5 Such desirable mutations can be obtained by screening large numbers of mutants for the increased activity as evidenced by an increase in B6 vitamer production as described in Example 4; or by selecting for mutants that are resistant to inhibitors that are specific for the PLP biosynthetic pathway, and screening among those mutants for an increase in B6 vitamer production. Examples of such inhibitors are isoniazid, iproniazid, and
- 10 ginkgotoxin (4'-methoxy pyridoxine) (Dempsey and Arcement (1971) J. Bacteriol. 107(2): 580-582; Pflug, W., and Lingens, F., (1978) Hoppe-Seyler's Z. Physiol. Chem. 359: 559-570; Fiehe, K., et al., (2000) J. Nat. Prod. 63(2): 185-189).

15 **EXAMPLE 8: Processing of biosynthetic B6 vitamers.**

- A B6 vitamer produced by a genetically modified organism of the invention can be harvested and processed into a format that is appropriate for commercial use. For example, after culturing a B6 vitamer producing micro-organism in liquid culture, the entire culture, including cells can be dried by evaporation or by spray
- 20 drying, and the resulting powder can be mixed into animal feeds. Alternatively, the cells can be first removed by centrifugation or filtration, and the resulting supernatant solution can be dried as described above. As another alternative, the B6 vitamer can be purified from the culture broth by techniques well known in the art, such as filtration, reverse osmosis, column chromatography (ion exchange, hydrophobic or hydrophilic
- 25 adsorption, gel filtration, etc.), solvent extraction, precipitation, distillation, evaporation, and the like. If the B6 vitamer producing organism is a plant, then the appropriate portion of the plant (for example the leaves, stems, roots, flowers, fruits, seeds, or any combination thereof) can be harvested and processed. For example the plant material can be dried and used directly, or the material can be pulverized or ground and the B6
- 30 vitamer extracted and/or processed as described above for cultures.

The production organism can be a micro-organism that normally inhabits the gut of humans or an animal of interest (for example one of many bacteria of the genus *Lactobacillus*, such as *L. acidophilus*), and the B6 vitamer can be delivered by ingestion of the organism.

Equivalents

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the

5 following claims.

60367863-032502

What is claimed:

1. An organism that has been genetically modified to comprise a recombinant DNA molecule that results in the increase of the activity of one or more enzymes that catalyze(s) a step in the biosynthesis of a B6 vitamer, such that B6 vitamer production from said modified organism is increased compared to B6 production in an unmodified parent organism.
2. The organism of claim 1, wherein B6 vitamer production is at least ten-fold higher than from the unmodified parent organism.
3. The organism of claim 1, wherein said enzyme is one or more of YaaD or YaaE.
4. The organism of claim 1, wherein said organism is genetically modified to overexpress one or more genes that encodes an enzyme that catalyzes a step in the biosynthesis of a B6 vitamer.
5. The organism of claim 4, wherein said genes are derived from *Bacillus*.
6. The organism of claim 4, wherein said genes are derived from *Bacillus subtilis*.
7. The organism of claim 4, wherein at least one of said genes is a *yaaD* gene.
8. The organism of claim 4, wherein at least one of said genes is a *yaaE* gene.
9. The organism of claim 4, wherein at least two of said genes are *yaaD* and *yaaE* genes.
10. The organism of claim 4, wherein said organism is a *Bacillus* strain.

60367863.032502



11. The organism of claim 4, wherein said organism is *Bacillus subtilis*.
12. The organism of any one of claims 1-11, wherein said organism is grown in a liquid culture and the total B6 vitamer concentration in the culture supernatant is at least 7.0 mg/liter.
13. A method of producing a B6 vitamer comprising culturing a microorganism that has been genetically modified to overexpress one or more genes that encodes an enzyme that catalyzes a step in the biosynthesis of a B6 vitamer, such that B6 vitamer production from said modified organism is increased compared to B6 production in an unmodified parent organism, under conditions such that the B6 vitamer is produced.
14. The method of claim 13, wherein said enzyme is one or more of YaaD or YaaE.
15. The method of claim 13, wherein at least one of said genes is a *yaaD* gene.
16. The method of claim 13, wherein at least one of said genes is a *yaaE* gene.
17. The method of claim 13, wherein said genes are contained on the *yaaDE* operon.
18. The method of claim 13, wherein the B6 vitamer is pyridoxine.
19. The method of claim 13, wherein the B6 vitamer is pyridoxal.
20. The method of claim 13, wherein the B6 vitamer is pyridoxamine.
21. The method of claim 13, wherein the said genes are bacterial-derived.
22. The method of claim 13, wherein said genes are derived from *Bacillus*.

60367863-032502

60367863.032562

23. The method of claim 13, wherein said genes are derived from *Bacillus subtilis*.
24. The method of claim 13, wherein the microorganism is Gram positive.
25. The method of claim 13, wherein the microorganism is a microorganism belonging to a genus selected from the group consisting of *Bacillus*, *Corynebacterium*, *Lactobacillus*, *Lactococci* and *Streptomyces*.
26. The method of claim 13, wherein the microorganism is of the genus *Bacillus*.
27. The method of claim 13, wherein the microorganism is *Bacillus subtilis*.
28. The method of claim 13, further comprising recovering the B6 vitamer.
29. A method of producing a B6 vitamer comprising culturing a microorganism that overexpresses at least one *Bacillus* B6 vitamer biosynthetic gene under conditions such that the B6 vitamer is produced.
30. The method of claim 29, wherein the microorganism overexpresses at least one *Bacillus subtilis* B6 vitamer biosynthetic enzyme.
31. The method of claim 29, wherein the B6 vitamer is pyridoxine.
32. The method of claim 29, wherein the B6 vitamer is pyridoxal.
33. The method of claim 29, wherein the B6 vitamer is pyridoxamine.
34. The method of claim 29, wherein the microorganism overexpresses at least two B6 vitamer biosynthetic enzymes.

60367863.032502

35. The method of claim 29, wherein the microorganism is Gram positive.
36. The method of claim 29, wherein the microorganism is Gram negative.
37. The method of claim 29, wherein the microorganism is a microorganism belonging to a genus selected from the group consisting of *Bacillus*, *Corynebacterium*, *Lactobacillus*, *Lactococci* and *Streptomyces*.
38. The method of claim 29, wherein the microorganism is of the genus *Bacillus*.
39. The method of claim 29, wherein the microorganism is *Bacillus subtilis*.
40. The method of claim 29, further comprising recovering the B6 vitamer.
41. A recombinant microorganism that overexpresses at least one *Bacillus* B6 vitamer biosynthetic gene.
42. A recombinant microorganism that overexpresses at least one *Bacillus* B6 vitamer biosynthetic enzyme.
43. The method of claim 42, wherein said enzyme is YaaD or YaaE.
44. The recombinant microorganism of claim 41 that overexpresses at least one *Bacillus subtilis* B6 vitamer biosynthetic gene.
45. The recombinant microorganism of claim 41, wherein the B6 vitamer biosynthetic gene is selected from the group consisting of *yaaD* and *yaaE*.
46. The recombinant microorganism of claim 41, that is Gram positive.

47. The recombinant microorganism of claim 41 belonging to a genus selected from the group consisting of *Bacillus*, *Corynebacterium*, *Lactobacillus*, *Lactococci* and *Streptomyces*.

5 48. The recombinant microorganism of claim 41 belonging to the genus *Bacillus*.

49. The recombinant microorganism of claim 41 which is *Bacillus subtilis*.

10

50. A recombinant microorganism selected from the group consisting of PX14 and PX17.

51. A vector comprising a nucleic acid sequence that encodes at least one *Bacillus* B6 vitamer biosynthetic gene operably linked to regulatory sequences.

15

52. The vector of claim 51, comprising a nucleic acid sequence that encodes at least one *Bacillus subtilis* B6 vitamer biosynthetic gene.

20

53. The vector of claim 51, wherein the regulatory sequences comprise a constitutively active promoter.

54. The vector of claim 51, wherein the constitutively active promoter comprises  $P_{15}$  (SEQ ID NO:9) or  $P_{26}$  (SEQ ID NO:10) sequences.

25

55. The vector of claim 51, wherein the regulatory sequences comprise at least one artificial ribosome binding site (RBS).

56. A vector selected from the group consisting of pDX14R and pDX17R.

30

57. A recombinant microorganism comprising the vector of claim 56.

58. An isolated nucleic acid molecule that encodes at least one *Bacillus* B6 vitamer biosynthetic gene.

35

1603167887.032502

59. The isolated nucleic acid molecule of claim 58 that encodes at least one *Bacillus subtilis* B6 vitamer biosynthetic gene.

60. An isolated *Bacillus* B6 vitamer biosynthetic enzyme polypeptide.

5

61. An isolated *Bacillus subtilis* B6 vitamer biosynthetic enzyme polypeptide.

60367863-032502

**METHODS AND ORGANISMS FOR  
PRODUCTION OF B6 VITAMERS**


**5    Abstract of the Disclosure**

The present invention features methods of producing B6 vitamers that involve culturing an organism overexpressing an enzyme that catalyzes a step in the biosynthesis of a B6 vitamer under conditions such that a B6 vitamer is produced. The

- 10   present invention further features methods of producing B6 vitamers that involve culturing recombinant microorganisms that overexpress at least one B6 vitamer biosynthetic gene, *e.g.*, *yaaD* or *yaaE*.

60367863-032502

Figure 1









205260-69873E09

Figure 3



**Figure 4. Structure of pDX1F**



60367863.032502

60367863-032502

**Figure 5. Structure of pDX11F**






Figure 6



60367863.032502

50367863-032502

FIGURE 7. *Structure of pDX17R*



## SEQUENCE LISTING

<110> Yocum, R. Rogers  
Williams, Mark K.  
Pero, Janice G.

<120> METHODS AND ORGANISMS FOR PRODUCTION OF B6 VITAMERS

<130> BGI-152-2

<160> 19

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 46

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 1

ccctctagag gaggagaaaa catggctcaa acaggtactg aacgtg

46

<210> 2

<211> 45

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 2

cccggatcct caactgtttt atacaagtcg cttttgctta tattc

45

<210> 3

<211> 49

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 3

ccctctagag gaggagacat aatggaacgt acaacgaatt ttaacgcag

49

<210> 4

<211> 41

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 4

cccggatccc ggacggtttg catagccaga ctttttactc a

41

<210> 5

<211> 5322

<212> DNA

50367863 032502

## &lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; plasmid - pDX1F

&lt;400&gt; 5

50367863 - 032502

tgcgccgcta	cagggcgcgct	ccattcgcca	ttcaggctgc	gcaactgttg	ggaagggcga	60
tcggtgcggg	cctcttcgct	attacgccag	ctggcgaaaag	ggggatgtgc	tgcaaggcga	120
ttaagttggg	taacgccagg	gttttccag	tcacgacgtt	gtaaaacgac	ggccagtga	180
ttgtaatacg	actcactata	gggcgaattg	ggcccgacgt	cgcatgctcc	cgcccgccat	240
ggccgcggga	tccctctaga	ggaggagaaa	acatggctca	aacaggtaact	gaacgtgtaa	300
aacgcggaat	ggcagaaatg	caaaaaggcg	cgctcatcat	ggacgtcatc	aatgcggaac	360
aagcgaaaat	cgctgaagaa	gctggagctg	tcgctgtaat	ggcgctagaa	cggtgcccag	420
cagatattcg	cgcggtgga	ggagttgccc	gtatggctga	ccctacaatc	gtggaagaag	480
taatgaatgc	agtatctatc	ccggtaatgg	caaaagcgcg	tatcggacat	attggtgaag	540
cgctgtgct	tgaagctatg	ggtgttgact	atattgatga	aagtgaagtt	ctgacgcggy	600
ctgacgaaga	atttcattta	aataaaaatg	aatacacagt	tccttttgtc	tgtggctgcc	660
gtgatcttgg	tgaagcaaca	cgccgtattg	cggaaggtgc	ttctatgctt	cgacaaaaag	720
gtgagcctgg	aacaggtaat	attggtgagg	ctgttcgccca	tatgcgtaaa	gttatcacta	780
gtgcggcgcc	ctgcaggtcg	accatatggg	agaggcgccc	gcgtcgacca	atagttaccc	840
ttattatcaa	gataagaaa	aaaaggattt	ttcgctacgc	tcaaatcctt	taaaaaaaca	900
caaaagacca	cattttttta	tgtggtcttt	attcttcaac	taaaagcacc	attagttcaa	960
caaacgaaaa	ttggataaag	tgggatattt	ttaaaatata	tatttatgtt	acagtaatat	1020
tgacttttta	aaaaggattg	attctaata	agaaagcaga	caagtaagcc	tcctaaattc	1080
acttttagata	aaaatttagg	aggcatatca	aatgaacttt	aataaaattg	atttagacaa	1140
ttggaagaga	aaagagatat	ttaatcatta	tttgaaccaa	caaacgactt	ttagtataac	1200
cacagaaatt	gatattagtg	ttttataccg	aaacataaaa	caagaaggat	ataaatttta	1260
ccctgcattt	attttcttag	tgacaagggt	gataaactca	aatacagctt	ttagaactgg	1320
ttacaatagc	gacggagagt	taggttattg	ggataagtta	gagccacttt	atacaatttt	1380
tgatggtgta	tctaaaacat	tctctggtat	ttggactcct	gtaaagaatg	acttcaaaga	1440
gttttatgat	ttataccttt	ctgatgtaga	gaaatataat	ggttcgggga	aattgtttcc	1500
caaaacacct	atacctgaaa	atgctttttc	tctttctatt	attccatgga	cttcatttac	1560
tgggttttaac	ttaaatatca	ataataatag	taattacctt	ctaccatta	ttacagcagg	1620
aaaattcatt	aataaaggta	attcaatata	tttaccgcta	tctttacagg	tacatcattc	1680
tgtttgat	ggttatcatg	caggattggt	tatgaactct	attcaggaat	tgtagatag	1740
gcctaataac	tggcttttat	aatatgagat	aatgccgact	gtacttttta	cagtcgggtt	1800
tctaattgtca	ctaacctgcc	ccgttagttg	aagaagggtt	ttatattaca	gctccggtac	1860
cgggctccca	acgcgttgga	tgcatagctt	gagtattcta	tagtgtcacc	taaataagctt	1920
ggcgtaatca	tggtcatagc	tgtttctgt	gtgaaattgt	tatccgaaca	ataggtgtac	1980
taggacttca	aggagcagtt	agagagcaca	tccatgcgat	tgaagcatgc	ggcgcggtg	2040
gtcttgctgt	aaaacgtccg	gagcagctga	acgaagtga	cgggttgatt	ttgccgggcy	2100
gtgagagcac	gacgatgcgc	cgtttgatcg	atacgtatca	attcatggag	ccgcttcgtg	2160
aattcgctgc	tcaggggcaa	ccgatgttg	gaacatgtgc	cggattaatt	atattagcaa	2220
aagaaattgc	cggttcagat	aatcctcatt	taggtcttct	gaatgtggtt	gtagaacgta	2280
attcatttgg	ccggcaggtt	gacagctttg	aagctgattt	aacaattaaa	ggcttgagcg	2340
agccttttac	tggggtattc	atccgtgctc	cgcatatttt	agaagctggt	gaaaatgttg	2400
aagttctatc	ggagcataat	ggtcgtattg	tagccgcgaa	acaggggcaa	ttccttggct	2460
gctcattcca	tccggagctg	acagaagatc	accgagtgac	gcagctgttt	gttgaaatgg	2520
ttgaggaata	taagcaaaa	gcacttgat	aaaacagttg	aggatccggg	atcactagtg	2580
cggccgcctg	caggtcgacc	atatgggaga	gctcccaacg	cgttggtatg	atagcttgag	2640
tattctatag	tgtaacctaa	atagcttggc	gtaatcatgg	tcatagctgt	ttcctgtgtg	2700
aaattgttat	ccgctcaca	ttccacacaa	catacgagcc	ggaagcataa	agtgtaaaag	2760
ctgggggtgcc	taatgagtga	gctaactcac	attaattgcy	ttgcgctcac	tgcccgcttt	2820
ccagtcggga	aacctgtcgt	gccagctgca	ttaatgaatc	ggccaacgcy	cggggagagg	2880
cggtttgctg	attgggcgct	cttccgcttc	ctcgctcact	gactcgctgc	gctcggtcgt	2940
tcggctgcgg	cgagcggtat	cagctcactc	aaaggcggtg	atacggttat	ccacagaatc	3000
aggggataac	cgaggaaaag	acatgtgagc	caaaaggccag	caaaaggcca	ggaaccgtaa	3060
aaaggccgcy	ttgctggcgt	ttttcgatag	gctccgcccc	cctgacgagc	atcacaaaaa	3120
tcgacgctca	agtcagaggt	ggcgaaaccc	gacaggacta	taaagatacc	aggcggtttc	3180
ccctggaagc	tccctcgtgc	gctctcctgt	tccgaccctg	ccgcttaccc	gatacctgtc	3240
cgcctttctc	ccttcgggaa	gcgtggcgct	ttctcatagc	tcacgctgta	ggtatctcag	3300

ttccggtgtag gtcgttcgct ccaagctggg ctgtgtgcac gaaccccccg ttcagccoga 3360  
 ccgctgcgcc ttatccggtg actatcgtct tgagtcacac ccggtaaagac acgacttate 3420  
 gccactggca gcagccactg gtaacaggat tagcagagcg aggtatgtag gcggtgctac 3480  
 agagtctctg aagtggtggc ctaactacgg ctacactaga aggacagtat ttggtatctg 3540  
 cgctctgctg aagccagtta ccttcggaaa aagagttggt agctcttgat ccggcaaaaa 3600  
 aaccaccgct ggtagcgggt gtttttttgt ttgcaagcag cagattacgc gcagaaaaaa 3660  
 aggatctcaa gaagatcctt tgatcttttc tacggggctc gacgctcagt ggaacgaaaa 3720  
 ctacagttaa gggatttttg tcatgagatt atcaaaaagg atcttcacct agatcctttt 3780  
 aaattaaaaa tgaagtttta aatcaatcta aagtatatat gagtaaaactt ggtctgacag 3840  
 ttaccaatgc ttaatcagtg aggcacctat ctacagcgtc tgtctatttc gttcatccat 3900  
 agttgcctga ctccccgtcg ttagataaac tacgatacgg gagggcttac catctggccc 3960  
 cagtgcctga atgataccgc gagaccacag ctacccggct ccagatttat cagcaataaa 4020  
 ccagccagcc ggaagggccg agcgagaaag tggctcctga actttatccg cctccatcca 4080  
 gtctattaat tgttgccggg aagctagagt aagtagttcg ccagttaata gtttgccgaa 4140  
 cgttggtggc attgctacag gcatcggtgt tcacgctcgc tcggttggtg tggcttcat 4200  
 cagctccggt tcccaacgat caaggcgagt tacatgatcc cccatgttgt gcaaaaaagc 4260  
 ggttagctcc ttccggtcctc cgatcggtgt cagaagtaag ttggccgcag tgttatcact 4320  
 catggttatg gcagcactgc ataattctct tactgtcatg ccatccgtaa gatgcttttc 4380  
 tgtgactggt gactactcaa ccaagtcatt ctgagaatac cgcgcccgcc gaccgagttg 4440  
 ctcttgcccg gcgtcaatac gggataatag tgtatgacat agcagaactt taaaagtgtc 4500  
 catcattgga aaacgtttt cgggcgaaaa actctcaagg atcttaccgc tgttgagatc 4560  
 cagttcgatg taaccactc gtgcacccaa ctgatcttca gcatctttta ctttaccag 4620  
 cgtttctggg tgagcaaaaa caggaaggca aaatgccgca aaaaaggga taaggcgac 4680  
 acggaatgt tgaatactca tactcttctt ttttcaatat tattgaagca tttatcaggg 4740  
 ttattgtctc atgagcggt acatatttga atgtatttag aaaaataaac aaataggggt 4800  
 tccgcgcaca ttcccccga aagtgccacc tgtatgcggt gtgaaatacc gcacagatgc 4860  
 gtaaggagaa aataccgcac cagcgcaaat tgtaaacgtt aatatattgt taaaattcgc 4920  
 gttaaatatt tgttaaatca gctcattttt taaccaatag gccgaaatcg gcaaaatccc 4980  
 ttataaatca aaagaataga ccgagatagg gttgagtgtt gttccagttt ggaacaagag 5040  
 tccactatta aagaacgtgg actccaacgt caaaggcgca aaaaccgtct atcagggcga 5100  
 tggcccacta cgtgaaccat caccctaaat aagttttttg cggctcgaggt gccgtaaagc 5160  
 tctaaatcgg aaccctaaag ggagcccccg atttagagct tgacggggaa agccggcgaa 5220  
 cgtggcgaga aaggaaaggga agaaagcgaa aggagcgggc gctagggcgc tggcaagtgt 5280  
 ageggtcacg ctgcgcgtaa ccaccacacc cgccgcgctt aa 5322

&lt;210&gt; 6

&lt;211&gt; 5297

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; plasmid - pDX11F

&lt;400&gt; 6

tgcgcgcta cagggcgct ccattcgcca ttcaggctgc gcaactgttg ggaagggcga 60  
 tcggtgcggg cctcttcgct attacgccag ctggcgaaag ggggatgtgc tgcaaggcga 120  
 ttaagtggg taacgccagg gttttccag tcacgacgtt gtaaaacgac ggccagtga 180  
 ttgtaatacg actcactata gggcgaaatt gggccgacgt cgcagtctcc cggccgccat 240  
 ggccgcggga tccctctaga ggaggagaca taatggaaac tacaacgaat tttaacgcag 300  
 gtcctgcagc gctgccactg gaagttctgc aaaaagcaca gaaagaattt attgatttta 360  
 acgaatccgg catgtctgtt atggagcttt cccaccgcag caaagagtat gaagcgtgtc 420  
 accaaaaagc gaaaagcctc ttaatcgaaac tgatgggcat tccggaagat tacgatatct 480  
 tgtttcttca aggcggggca agccttcaat tctcaatgct tccgatgaac tttttaacac 540  
 ctgaaaaaac cgacattttt gtgatgaccg gcgcttggtc tgaaaaagca ctggcagaaa 600  
 cgaaactgtt cggaacacg totatcacgc tacaagtga aacagacaat tacagttata 660  
 ttccagaggt tgaccttacg gatgtaaaag acggcgcata tttacatatc acatccaaca 720  
 atacaatttt cggcactcag tggcaggagt ttccgaattc tccaattccg ctctagaccg 780  
 acatgtccag cgatatttta agcagaaaaa tcgatgtgtc caaatttgat gtgatctacg 840  
 gaggcacac tagtgcggcc gcctgcagggt cgaccatatt ggagaggcgg ccgcgtcgac 900



150367863.032502

caatagttac	ccttattatc	aagataagaa	agaaaaggat	ttttcgctac	gctcaaattcc	960
tttaaaaaaa	cacaaaagac	cacatttttt	aatgtggtct	ttattcttca	actaaagcac	1020
ccattagttc	aacaaacgaa	aattggataa	agtgggatat	ttttaaaata	tatatattatg	1080
ttacagtaat	attgactttt	aaaaaaggat	tgattctaat	gaagaaagca	gacaagtaag	1140
cctcctaaat	tcacttttaga	taaaaattta	ggaggcatat	caaatgaact	ttataaaaaat	1200
tgatttagac	aattggaaga	gaaaagagat	atttaatcat	tatttgaacc	aacaaacgac	1260
ttttagtata	accacagaaa	ttgatattag	tgttttatac	cgaaacataa	aacaagaagg	1320
atataaaatt	taccctgcat	ttattttctt	agtgaacaagg	gtgataaaact	caaatacagc	1380
ttttagaact	gggtacaata	gcgacggaga	gttaggttat	tgggataagt	tagagccact	1440
ttatacaatt	tttgatgggtg	tatctaaaac	attctctggt	atttggactc	ctgtaaagaa	1500
tgacttcaaa	gagttttatg	atttataacct	ttctgatgta	gagaaatata	atggttccggg	1560
gaaattgttt	cccaaaacac	ctataacctga	aaatgctttt	tctctttcta	ttattccatg	1620
gacttcattt	actgggttta	acttaaatat	caataataat	agtaattacc	ttctacccat	1680
tattacagca	ggaaaattca	ttaataaagg	taattcaata	tatttaccgc	tatctttaca	1740
ggtacatcat	tctgtttgtg	atggttatca	tgcaggattg	tttatgaact	ctattcagga	1800
attgtcagat	aggcctaag	actggctttt	ataatatgag	ataatgccga	ctgtactttt	1860
tacagtcggt	tttctaattg	cactaacctg	ccccgttagt	tgaagaagg	ttttatatta	1920
cagctccggt	accgggctcc	caacgcgttg	gatgcatagc	ttgagtattc	tatagtgtca	1980
cctaaatagc	ttggcgtaat	catggtcata	gctgtttcct	gtgtgaaatt	gttatccgta	2040
gtcatcatga	aaaaaagctg	gctgcaaaat	gaaaatgcga	acgtcccaaa	aatcttgaaa	2100
tattccacgc	atgtcaaagc	ggattcactc	tacaacactc	cgccgacatt	tgcgatttat	2160
atgctgagcc	tcgttctgga	atggctcaag	gaaaacggcg	gtgtggaagc	tggtgaacag	2220
cgcaatgaac	aaaaagcgca	ggttctctac	agctgtattg	atgaaagcaa	cggcttctat	2280
aaaggacatg	ccagaaaaga	cagccgctca	cgcatgaatg	tcacattcac	gcttcgggat	2340
gacgaattaa	cgaaaacatt	cgttcagaaa	gcaaaaagatg	cgaagatgat	cggccttggc	2400
ggacaccggt	cggtgggagg	ctgccgcgct	tctatttata	acgcggtctc	tctcgaagac	2460
tgtgaaaaat	tagctgcgtt	catgaagaaa	ttccagcagg	aaaatgagta	aaaagtctgg	2520
ctatgcattc	cgtccgggat	ccgggatcac	tagtgcggcc	gcctgcagg	cgaccatag	2580
ggagagctcc	caacgcgttg	gatgcatagc	ttaggtattc	tatagtgtca	cctaaatagc	2640
ttggcgtaat	catggtcata	gctgtttcct	gtgtgaaatt	gttatccgct	cacaattcca	2700
cacaacatac	gagccggaag	cataaaagtgt	aaagcctggg	gtgcctaag	agtgcgtaa	2760
ctcacattaa	ttgogttgcy	ctcactgccc	gctttccagt	cgggaaacct	gtcgtgccag	2820
ctgcattaat	gaatcgcca	acgcgcgggg	agaggcggtt	tgcgtattgg	gcgctcttcc	2880
gcttctctgc	tcactgactc	gctgcgctcg	gtcggtcggc	tgcggcgagc	ggatcagct	2940
cactcaaagg	cggtaatagc	gttatccaca	gaatcagggg	ataacgcagg	aaagaacatg	3000
tgagcaaaag	gccagcaaaa	ggccagggaac	cgtaaaaagg	ccgcgttgct	ggcggttttc	3060
gataggtctc	gccccctga	cgagcatcac	aaaaatcgac	gctcaagtca	gaggtggcga	3120
aaccgcagac	gactataaag	ataccaggcg	tttccccctg	gaagctccct	cgtgcgctct	3180
cctgtttccga	ccctgccgct	taccggatac	ctgtccgcct	ttctcccttc	gggaagcggtg	3240
gcgctttctc	atagctcacg	ctgtagggtat	ctcagttcgg	tgtaggtcgt	tcgctccaag	3300
ctgggctgtg	tgcacgaacc	ccccgttcag	ccgcacgcgt	gcgccttata	cggtactaat	3360
cgtcttgagt	ccaaccgggt	aagacacgac	ttatcgccac	tggcagcagc	cactggtaac	3420
aggattagca	gagcgaggta	tgtaggcggt	gctacagagt	tcttgaagtg	gtggcctaac	3480
tacggctaca	ctagaaggac	agtatttgg	atctgcgctc	tgtgaagcc	agttaccttc	3540
ggaaaaaagag	ttggtagctc	ttgatccggc	aaacaaacca	ccgctggtag	cgttggtttt	3600
tttgtttgca	agcagcagat	tacgcgcaga	aaaaaaggat	ctcaagaaga	tcctttgatc	3660
ttttctacgg	ggtctgacgc	tcagtggaaac	gaaaactcac	gttaagggat	tttgggtcatg	3720
agattatcaa	aaaggatctt	cacctagatc	cttttaaat	aaaaatgaag	ttttaaatca	3780
atctaaagta	tatatgagta	aacttgggtct	gacagttacc	aatgcttaat	cagtgaggca	3840
cctatctcag	cgatctgtct	atttctgttca	tccatagtgt	cctgactccc	cgtogttag	3900
ataactacga	tacgggagg	cttaccatct	ggccccagtg	ctgcaatgat	accgcgagac	3960
ccacgctcac	cggctccaga	tttatcagca	ataaaccagc	cagccggaag	ggccgagcgc	4020
agaagtggtc	ctgcaacttt	atccgcctcc	atccagtcta	tttaattgtt	ccgggaagct	4080
agagtaagta	gttcgccagt	taatagtttg	cgcaacggtg	ttggcattgc	tacaggcatc	4140
gtggtgtcac	gctcgctggt	tgggtatggct	tcattcagct	ccggttccca	acgatcaagg	4200
cgagttacat	gatcccccat	gttgtgcaaa	aaagcggtta	gctccttcgg	tcctccgatac	4260
gttgtcagaa	gtaagttggc	cgcagtgtta	tcactcatgg	ttatggcagc	actgcataat	4320
tctcttactg	tcatgccatc	cgtaagatgc	ttttctgtga	ctggtgagta	ctcaaccaag	4380
tcattctgag	aataccgcgc	ccggcgaccg	agttgctctt	gcccggcgctc	aatacgggat	4440
aatagtgtat	gacatagcag	aactttaaaa	gtgctcatca	ttggaaaacg	ttcttcgggg	4500
cgaaaactct	caaggatctt	accgctgttg	agatccagtt	cgatgtaacc	cactcgtgca	4560

```

cccaactgat cttcagcatc ttttactttc accagcggtt ctgggtgagc aaaaacagga 4620
aggcaaaaatg ccgcaaaaaa gggaataagg gcgacacgga aatggtgaat actcatactc 4680
ttcctttttc aatattattg aagcatttat cagggttatt gtctcatgag cggatacata 4740
tttgaatgta tttagaaaaa taaacaaata ggggttccgc gcacatttcc ccgaaaagt 4800
ccacctgtat gcggtgtgaa ataccgcaca gatgcgtaag gagaaaatac cgcacaggc 4860
gaaattgtaa acgttaatat tttgttaaaa ttcgcgttaa atatttgta aatcagctca 4920
tttttaacc aataggccga aatcggaaca atcccttata aatcaaaaga atagaccgag 4980
atagggttga gtgtgttcc agtttgaac aagagtccac tattaagaa cgtggactcc 5040
aacgtcaaag gcgcaaaaac cgtctatcag ggcgatggcc cactacgtga accatcaccc 5100
aaatcaagtt ttttgcggtc gaggtgcggt aaagctctaa atcggaaccc taaaggggagc 5160
ccccgattta gagcttgacg gggaaagccg gcgaacgtgg cgagaaagga agggaagaaa 5220
gcgaaggag cgggcgctag ggcgctggca agtgtagcgg tcacgctgcg cgtaaccacc 5280
acaccgcgcg cgcttaa
5297

```

&lt;210&gt; 7

&lt;211&gt; 6731

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; plasmid - pDX14R

&lt;400&gt; 7

```

ttgcccgcg ttcgaaagct gtaatatataa aacotttctc aactaacggg gcagggttagt 60
gacattagaa aaccgactgt aaaaagtaca gtccgcatta tctcatatta taaaagccag 120
tcattaggcc tatctgacaa ttctgaata gagttcataa acaatcctgc atgataacca 180
tcacaaacag aatgatgtac ctgtaaagat agcggtaaat atattgaatt acctttatta 240
atgaattttc ctgctgtaat aatgggtaga aggttaattac tattattatt gatatttaag 300
ttaaaccag taaatgaagt ccatggaata atagaaagag aaaaagcatt ttcagggtata 360
ggtgttttgg gaaacaattt ccccgaaacca ttatatctct ctacatcaga aagggtataaa 420
tcataaaaact ctttgaagtc attcttttca ggagtcctaaa taccagagaa tgtttttagat 480
acaccatcaa aaattgtata aagtggctct aacttatccc aataacctaa ctctccgtcg 540
ctattgtaac cagttctaaa agctgtattt gagtttatca ccctgtgcac taagaaaata 600
aatgcagggt aaaatttata tcttcttctg tttatgtttc ggtataaaac actaatatca 660
atttctgtgg ttatactaaa agtcgtttgt tggttcaaat aatgattaaa tatctctttt 720
ctcttccaat tgtctaaatc aattttatta aagttcattt gatatgcctc ctaaaattttt 780
atctaaagtg aatttaggag gcttatttgt ctgctttctt cattagaatc aatccttttt 840
taaaagtcaa tattactgta acataaatat atatttttaa aatatccac tttatccaat 900
tttcgtttgt tgaactaatg ggtgctttag ttgaagaata aagaccacat taaaaaatgt 960
ggtcttttgt gtttttttaa aggatttgag cgtagcgaaa aatccttttc tttcttatct 1020
tgataataag ggtaactatt gaattcggtt ccaagagttt gtagaaacgc aaaaaggcca 1080
tccgtcagga tggccttctg cttaatttga tgccctggcag tttatggcgg gcgtccctgc 1140
cgccaccctc cgggcggttg cttcgcaacg ttcaaatccg ctcccggcgg atttgcctca 1200
ctcaggagag cgttcaccga caaacaacag ataaaaacgaa aggccagtc tttcgactga 1260
gcctttcgtt ttatttgatg cctggcagtt ccctactctc gcattggggag accccacact 1320
accatcggcg ctacggcggtt tcacttctga gttcggcatg gggtcagggt ggaccaccgc 1380
gctactgccg ccaggcaaat tctgttttat cagaccgctt ctgctgtctg atttaatctg 1440
tatcaggctg aaaatcttct ctcactcgcc aaaacaggat cctcaactgt tttatacaag 1500
tgccctttgc ttatatctct caaccatttc acaaacagc tgctgactc ggtgatcttc 1560
tgtcagctcc ggatggaatg agcagccaag gaattgcgcc tgtttcgcg ctacaatacg 1620
accattatgc tccgatagaa cttcaacatt ttcaccagct tctaaaatat gcggagcacg 1680
gatgaatacc ccagtaaaag gctcgtccaa gcctttaatt gttaaatcag cttcaaagct 1740
gtcaacctgc cggccaaatg aattacgttc tacaaccaca ttcagaagac ctaaatgagg 1800
attatctgaa cgggaattt cttttgctaa tataattaat ccggcacatg ttccaaacat 1860
cggtttgccc tgagcagcga attcagcag cggctccatg aattgatacg tatcgatcaa 1920
acggcgcatc gtcgtgctct caccgcccgg caaaatcaac ccgtcaactt cggtcagctg 1980
ctccggacgt tttacgacaa gaccagccgc gccgcatgct tcaatcgcat ggatgtgctc 2040
tctaactgct ccttgaagtc ctagtacacc tattgttaac atgtcagcag cgctcctatg 2100
ttcttaccag ccgcgttctt gcatacgtg ttctggaagt aagtttgaga tttcaatccc 2160

```

60367863.032502

BGI-152-2-042502

tttcattgca	gtaccaagct	cttttgacaa	ctcagcgatt	aattttgtaat	cagtaaagtg	2220
agtgtgtgct	tccacaattg	ctttcgcaaa	tttagcaggg	ttgtctgatt	taaaaatacc	2280
agaaccaaca	aatactccgt	cagcaccag	ctgcatcatg	agagcagcat	cagctggagt	2340
tgctacgccg	ccagcgccaa	agttaacgac	aggaagottg	ccgtcttttt	taatttgaa	2400
aagaagctcg	taaggagcac	ctaggttttt	cgcttctgtc	attagctcat	cctcaactcat	2460
cgcaactact	ttgogcactt	gagcggtaac	tttacgcata	tggcgaacag	cctcaacaat	2520
attacctgtt	ccaggctcac	cttttgtgcy	aagcatagaa	gcaccttcg	caatacggcg	2580
tggtgtctca	ccaagatcac	ggcagccaca	gacaaaagga	actgtgtatt	cattttttatt	2640
taaatgaaat	tcttcgtcag	ccggcgtcag	aacttcactt	tcatacaat	agtcacaacc	2700
catagottca	agcacacgcy	cttcaacaat	atgtccgata	cgcgcttttg	ccattaccgg	2760
gatagatact	gcattcatta	cttcttccac	gattgtaggg	tcagccatac	gggcaactcc	2820
tcagacccgc	cgaatatctg	ctggcacacg	ttctagcgcc	attacagcga	cagctccagc	2880
ttcttcagcg	attttcgctt	gttccgcatt	gatgacgtcc	atgatgacgc	cgcttttttg	2940
cattttctgcc	attccgcgtt	ttacacgttc	agtacctgtt	tgagccatgt	tttctcctcc	3000
tctagagcgt	cctgctgttg	ttaaagattat	tataccacac	cttgtagata	aagtcaacaa	3060
ctttttgcaa	aatttttcag	gaatttttagc	agaggttggt	ctggatgtag	aacaaaacat	3120
ctttccgctc	ttgtgctgtt	aggatatctt	tcttggaagc	taggtaggcc	tcgagttatg	3180
gcagttgggt	aaaaggaaac	aaaaagaccg	ttttcacaca	aaacggctct	tttcgatttc	3240
tttttacagt	cacagccact	tttgcaaaaa	ccggacagct	tcatagcctta	taactgctgt	3300
tccggtcgac	ctgcaggcat	gcaagcttcg	cgaagcgggc	gcgacgcga	ggctggatgg	3360
cttcccccct	tatgattctt	ctcgcttcgg	gcggcatcgg	gatgcccgcg	ttgcaggcca	3420
tgctgtccag	gcaggtagat	gacgaccatc	agggacagct	tcaaggatcg	ctcgcggctc	3480
ttaccagcct	aacttcgatc	actggaccgc	tgatcgtcac	ggcgatttat	gccgcctcgg	3540
cgagcacatg	gaacgggttg	gcatggattg	taggcgcgcg	cctatacctt	gtctgcctcc	3600
ccgcgttgcg	tcgcgggtga	tggagccggg	ccacctcgac	ctgaatggaa	gccggcgcca	3660
cctcgttaac	ggattcacca	ctccaagaat	tggagccaat	caattcttgc	ggagaactgt	3720
gaatgcgcaa	accaaccctt	ggcagaacat	atccatcgcg	tccgccatct	ccagcagccg	3780
cacgcggcgc	atctcggggc	gcgttgggtc	gtggccacgg	gtgcgcagta	tcgtgctcct	3840
gtcgttgagg	accgggctag	gctggcgggg	ttgccttact	ggttagcaga	atgaatcacc	3900
gatacgcgag	cgaacgtgaa	gcgactgctg	ctgcaaaacg	tctgcgacct	gagcaacaac	3960
atgaatggtc	ttcgggtttcc	gtgtttcgta	aagtctggaa	acgcgggaag	cagcgccctg	4020
caccattatg	ttccggatct	gcacgcaggg	atgctgctgg	ctacctgtg	gaacacctac	4080
atctgtatta	acgaagcgct	ggcatggacc	ctgagtgatt	tttctctggt	cccgcgcgat	4140
ccataccgcc	agttgtttac	cctcacaaac	ttccagtaac	cgggcaggtt	catcatcagt	4200
aaccgcgtac	gtgagcatcc	tctctcgttt	catcggtatc	attaccccca	tgaacagaaa	4260
ttccccctta	cacggaggca	tcaagtgacc	aaacaggaaa	aaaccgcctt	taacatggcc	4320
cgctttatca	gaagccagac	attaacgctt	ctggagaaac	tcaacgagct	ggacgcggat	4380
gaacaggcag	acatctgtga	atcgcttcac	gaccacgctg	atgagcttta	ccgcagctgc	4440
ctcgcgcggt	tcgggtgatga	cggtgaaaac	ctctgacaca	tgacagctccc	ggagacgggt	4500
acagcttgct	tgtaaagcga	tggcgggagc	agacaagccc	gtcagggcgc	gtcagcggtc	4560
gttggcgggt	gtcggggcgc	agccatgacc	cagtcacgta	gcgatacgcg	agtgtatact	4620
ggcttaacta	tgcggcatca	gagcagattg	tactgagagt	gcacatatg	cgggtgtgaa	4680
taccgcacag	atgcgtaagg	agaaaatacc	gcacagcgcg	ctcttccgct	tctcgcgtca	4740
ctgactcgct	gcgctcggtc	gttcggctgc	ggcgagcggt	atcagctcac	tcaaaggcgg	4800
taatacgggt	atccacagaa	tcagggggata	acgcaggaaa	gaacatgtga	gcaaaaggcc	4860
agcaaaaggc	caggaaccgt	aaaaaggccg	cgttgctggc	gtttttccat	aggctccgcc	4920
cccctgacga	gcatacaaaa	aatcgacgct	caagtcagag	gtggcgaaac	ccgacaggac	4980
tataaagata	ccaggcggtt	ccccctggaa	gtccctcgt	gcgctctcct	gttccgaccc	5040
tgcgcgttac	cggatacctg	tccgcctttc	tcccttcggg	aagcgtggcg	ctttctcata	5100
gctcacgctg	taggtatctc	agttcggtgt	aggtggttcg	ctccaagctg	ggctgtgtgc	5160
acgaaccccc	cgttcagccc	gaccgctgcg	ccttatccgg	taactatcgt	cttgagtcca	5220
acccggttaag	acacgactta	tcgccactgg	cagcagccac	tggtaacagg	attagcagag	5280
cgaggatagt	aggcggtgct	acagagttct	tgaagtgggt	gcctaactac	ggctacacta	5340
gaaggacagt	atttggtatc	tgcgctctgc	tgaagccagt	taccttcgga	aaaagagttg	5400
gtagctcttg	atccggcaaa	caaaccaccg	ctggtagcgg	tgggtttttt	gtttgcaagc	5460
agcagattac	gdcgagaaaa	aaaggatctc	aagaagatcc	tttgatcttt	tctacggggg	5520
ctgacgctca	gtggaacgaa	aactcacggt	aaggagtttt	ggctcatgaga	ttatcaaaaa	5580
ggatcttcac	ctagatcctt	ttaaattaaa	taagtgaatt	taaatcaatc	taagtatat	5640
atgagtaaac	ttggtctgac	agttaccaat	gcttaatcag	tgaggcacct	atctcagcga	5700
tctgtctatt	tcgttcatcc	atagttgcct	gactccccgt	cgtgtagata	actacgatac	5760
gggaggggct	accatctggc	cccagtgctg	caatgatacc	gcgagaccca	cgctcaccgg	5820

```

ctccagattt atcagcaata aaccagccag ccggaagggc cgagcgcaga agtgggtcctg 5880
caactttatc cgcctccatc cagtctatta attgttgccg ggaagctaga gtaagtagtt 5940
cgccagttaa tagtttgccg aacgttggtg ccattgctgc aggcacgtg gtgtcacgct 6000
cgctggttgg tatggettca ttcagctcog gttcccaacg atcaaggcga gttacatgat 6060
ccccatggt gtgcaaaaaa gcggttagct ccttcgggtc tccgatcgtt gtcagaagta 6120
agttggccgc agtggtatca ctcatggtta tggcagcact gcataattct cttactgtca 6180
tgccatccgt aagatgcttt tctgtgactg gtgagtactc aaccaagtca ttctgagaat 6240
agtgtatgcg gcgaccgagt tgctcttgcc cggcgtcaat acgggataat accgcgccac 6300
atagcagaac tttaaaagtg ctcatcattg gaaaaagttc ttcggggcga aaactctcaa 6360
ggatcttacc gctgttgaga tccagttcga tgtaaccac tctgacacc aactgatctt 6420
cagcatcttt tactttcacc agcgtttctg ggtgagcaaa aacaggaagg caaaatgccg 6480
caaaaaaggg aataagggcg acacggaat gttgaatact cataactctt ctttttcaat 6540
attattgaag catttatcag ggttattgtc tcatgagcgg atacatattt gaatgtattt 6600
agaaaaataa acaaataggg gttccgcgca catttccccg aaaagtgcc cctgacgtct 6660
aagaaaccat tattatcatg acattaacct ataaaaatag gcgtatcacg aggccttttc 6720
gtcttcaaga a

```

&lt;210&gt; 8

&lt;211&gt; 10181

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; plasmid - pDX17R

&lt;400&gt; 8

```

gaattttgcg gccgcttcga aagctgtaat ataaaaacct tcttcaacta acggggcagg 60
ttagtgacat tagaaaaccg actgtaaaaa gtacagtcgg cattatctca tattataaaa 120
gccagtcatt aggcctatct gacaattcct gaatagagtt cataaacaat cctgcatgat 180
aaccatcaca aacagaatga tgtacctgta aagatagcgg taaatatatt gaattacott 240
tattaatgaa ttttcctgct gtaataatgg tagaaggta attactatta ttattgatat 300
ttaagttaaa ccagtaaat gaagtccatg gaataataga aagagaaaaa gcattttcag 360
gtataggtgt tttgggaaac aatttccccg aaccattata tttctctaca tcagaaaggt 420
ataaatcata aaactctttg aagtcattct ttacaggagt ccaaatacca gagaatgttt 480
tagatacacc atcaaaaatt gtataaagtg gctctaactt atcccaataa cctaactctc 540
cgtcgctatt gtaaccagtt ctaaaagctg tatttgagtt tatcaccctt gtcactaaga 600
aaataaatgc agggtaaat ttatatcctt cttgttttat gtttcggtat aaaacactaa 660
tatcaatttc tgtggttata ctaaaagtcg tttgttggtt caaataatga ttaaatatct 720
ctttctctct ccaattgtct aaatcaattt tattaaagtt catttgatat gcctcctaaa 780
tttttatcta aagtgaattt aggaggctta cttgtctgct ttcttcatta gaatcaatcc 840
ttttttaaaa gtcaatatta ctgtaacata aatatatatt ttaaaaatat ccactttat 900
ccaattttcg tttgttgaa taatgggtgc tttagttgaa gaataaagac cacattaaaa 960
aatgtggtct tttgtgttt tttaaaaggat ttgagcgtag cgaaaaatcc ttttctttct 1020
tatcttgata ataagggtaa ctattgaatt cgttaccaag agtttgtaga aacgcaaaaa 1080
ggccatccgt caggatggcc ttctgcttaa tttgatgcct ggcagtttat ggcgggcgtc 1140
ctgccgccca ccctccgggc cgttgcttog caacgttcaa atccgctccc ggcggatttg 1200
tcctactcag gagagcgttc accgacaaac aacagataaa acgaaaggcc cagtctttcg 1260
actgagcctt tcgttttatt tgatgcctg cagttcccta ctctcgcatg gggagacccc 1320
acactacat cggcgtacg gcgtttcact tctgagttcg gcatggggtc aggtgggacc 1380
accgcgtac tgcgccagg caaattctgt tttatcagac cgcttctcgc ttctgattta 1440
atctgtatca ggctgaaaat cttctctcat ccgcaaaaac aggatcctca actgttttat 1500
acaagtgcct tttgcttata ttctcaacc atttcaacaa acagctgcgt cactcgggtg 1560
tcttctgtca gctccggatg gaatgagcag ccaaggaatt gccctgttt cgcggctaca 1620
atcgcacct tatgctcga tagaacttca acattttcac cagtttctaa aatatgcgga 1680
gcaeggatga atacccaggt aaaaggcttc tccaagcctt taattgttaa atcagcttca 1740
aagctgtcaa cctgccggcc aaatgaatta cgttctacaa ccacattcag aagacctaaa 1800
tgaggattat ctgaaccggc aatttctttt gctaataata ttaatccggc acatgttoca 1860
aacatcgggt tgccctgagc agcgaattca cgaagcggct ccatgaattg atacgtatcg 1920
atcaaacggc gcatcgtcgt gctctcaccg cccggcaaaa tcaaccogtc aacttcgttc 1980

```

60367853-032502

agctgctccg gacgttttac gacaagacca gccgcgccgc atgcttcaat cgcattgatg 2040  
 tgctctctaa ctgctccttg aagtcctagt acacctattg ttaacatgtc agcagcgctc 2100  
 ctatgttctt accagccgcg ttcttgcata cgctgttctg gaagtaagtt tgagatttca 2160  
 atccctttca ttgcagtacc aagctctttt gacaactcag cgattaattt gtaatcagta 2220  
 aagtgaagtt ttgttccac aattgctttc gcaaatttag cagggttgte tgatttataa 2280  
 ataccagaac caacaaatac tccgtcagca ccaagctgca tcatgagagc agcatcagct 2340  
 ggagttgcta cgcgcgccgc ggcaaagtta acgacaggaa gcttgccgtc ttttttaatt 2400  
 tgaagaagaa ctctgtaagg agcacctagg ttttctgctt ctgtcattag ctcatcctca 2460  
 ctcatcgcaa ctactttgcg cacttgagcg ttaactttac gcatatggcg aacagcctca 2520  
 acaatattac ctgttccagg ctacactttt gtgcgaagca tagaagcacc ttccgcaata 2580  
 cggcgtgttg cttcaccaag atcacggcag ccacagacaa aaggaactgt gtattcattt 2640  
 ttattttaa gaaattcttc gtcagccggc gtcagaactt cactttcatc aatatagtca 2700  
 acacccatag cttcaagcac acgcgcttca acaatatgtc cgatacgcgc ttttgccatt 2760  
 accgggatag atactgcatt cattaactct tccacgattg tagggtcagc catacgggca 2820  
 actcctccag cgcgcgcaat atctgctggc acacgttcta gcgccattac agcgacagct 2880  
 ccagcttctt cagcgatttt cgcttgctcc gcattgatga cgtccatgat gacgcccct 2940  
 ttttgcaatt ctgccattcc gcgttttaca cgcttcagta ctgtttgagc catgttttct 3000  
 cctcctctag aacaggcggg gttgcccccg cctgtaatta aattattaca caccctgtag 3060  
 ggaaagtcaa tacctttttt taaaattttt acacagcggt gatctcttct agggacacct 3120  
 cttgtaccc ctcaaggag aaatattggc ggtactgagc acagttttgg ttggtggaca 3180  
 gtgaaccata gctgtcgta atagcctcga gttatggcag ttggttaaaa ggaaacaaa 3240  
 agaccgtttt cacacaaaac ggtctttttc gatttctttt tacagtcaca gccacttttg 3300  
 caaaaacgg acagcttcat gccttataac tgctgtttcg gtcgacgatg atctgcccgt 3360  
 ttcttctgca agccaaaaa ccttccgtta caacgagaag gattcttcac tttctaaagt 3420  
 tcggcgagtt tcatcctct gtcccagtc tttttggat caaggcagac tgctgcaatg 3480  
 tctatctatt ttaataatag gtgcagttcg caggcgatac tgcccaatgg aagtatacca 3540  
 aaatcaacgg gcttgtaaca acacattagc ccaattcgat atcggcagaa tagattttt 3600  
 taatgccttc gttcgtttct aaaagcagaa cgccttoatc atctatacct aacgccttac 3660  
 cgtaaaaggt tccgtttaac gttctggctc tcatattagt gccaataacc agcgcatagc 3720  
 tttcccataa aagcttaatc ggcgtaaatc cgtgcgtcat ataatcccgg taccgtttct 3780  
 caaagcatag taaaatatgc tggatgacgc cggcccgatc aattttttcc ccagcagctt 3840  
 ggctgaggtc tgctgcgatg tccttcaatt catctggaaa atcattaggc tgctggttaa 3900  
 cgtaaatgcc gatcccaatg atcactgaac gtacgcgggtc ttcttcagcc tgcatttccg 3960  
 ttaggatacc gactgttttt tttccgttaa tcaaaaatc atttggccat ttaatatccg 4020  
 tttggatgcc tgctgcctct tctattccct gcacaacagc tactgcagca agcagagta 4080  
 gctgcgggtg tttttggagc ggaatgtcag gccgcaaat caggctcatc caaacaccgt 4140  
 ttcttcttg agaatgccat accctagaca ttccggccct tccggctgtt tgttgtcag 4200  
 ccaccacaag ggtgccttcc ggtgcgttat tattcgcgag ctcatgagcc gttttttgcg 4260  
 tgcttgaaag aacgtcatgg taaataagat gctggcccat cacttccgtt tttaatccaa 4320  
 aacgaatttc gctttcactg agttttccgg gctttttgat gagccgatat ccttttctc 4380  
 taacggcttc tacttcataa cctcttttcc gaagctcttc aatatgcttc cacacagcag 4440  
 ttcttgaaca gcgagagca tcaactgatt tttggccgga aataaattca ttgcggcct 4500  
 gagaaaataa ttcaataagg tcttttctta atgttgacc catgtcttca gccactctc 4560  
 tatgtgtttc ttttgattgg agagcttccc tgtcacaaca gcctgctoga tccactgtaa 4620  
 ttcttctgac acccatttcc cggccggccg gtttogaagc gcaagcaagt ccttaccct 4680  
 gatatacaga tcttaaggc ttttgatcgg caggttttga taagcgtact gaatgtcctt 4740  
 cagtttcttt tcatccagtt tttcgtttg ccgaagctgc gatattttgg ccgctgagag 4800  
 cagtgccttt tcccagctc tgtacattgt cattgcgtca aggtctctggc caaacgtatc 4860  
 ggcaatgtga atggcttcc tcatcacttt tcccgggagc ttccaggctt tcaggaaaag 4920  
 gggcgctct ttcaaaaacta tgccaaggtt aattaaaaga gcagccaaa gtcctcagc 4980  
 ggatgttaaa gagaagaatg gaaactcact cgttgaaatc aggttttctc gtttatgata 5040  
 aaaaccagga agctcttcat acaatctcgt ttgaatgagt gtttgaagcg cctggcgaga 5100  
 agctcttccc tgcagcaatt tctcaaaact tatagtttt cgcttcgactg aaacatggga 5160  
 gaggagtgat ttttctttog caatggcttc ttctgtttcc ggtgaaagcg taaagccaag 5220  
 ctggctcata aagcgtacgg ctctcagcat acgaagcgca tctcttgaa atctatctc 5280  
 aggttttcca acggttcgaa tcaactttctg atcaatatct ttcttgccgc caaaataatc 5340  
 aagcaccttc cgtccgctg tcatggccat cgcattgatc gttaaatctc tcggttttag 5400  
 atctcttctt aatgatgaga taaattgcac ttctgacggt cttctgaaat caacataatc 5460  
 agattcagtc cggaatgtcg tgacttcata ggtttcatcc tcccagagca caataatggt 5520  
 cccgtgctct ttgcctacat caacagtcgg ctgaaacagc cgttctactt gatcaggtgc 5580  
 cgcattctgtc gcgatatcga catctccgat cgcttcttcc atatagctgt cacgaactgc 5640

60367863.032502  
 202502

60367863-032502

```

gcccccgaca aaataagcct gatggcccgcg ttcgattaag atgcgaggca cgggaagtgc 5700
tttgataaaa actttttcca tgtgatcact cgggttctgc taaatcggca taaatctggt 5760
catactggct gacaattttt ttagaagaaa attcattttc aagcatctct attgccgct 5820
ttgtaaaacg attgcttagc tgttcattct ctaaaatgct catcgcgcg gctgttgcg 5880
ccgtaacatc accgacatcc accaaaaatc cgctcacatt gttttttata acctcaggga 5940
taccgccaat gtttgttcca atacaaggca ctccgcaagc catcgcttca agcaggacaa 6000
ggccaaagct ttctttttca gatagcagca gcttcaaate gctaatagaa taaagatctt 6060
caacacggct ttgattttca agcattaaga cttggtcttc caagccatat tttctgataa 6120
gctcgaggc tgtcgatttc tccggaccgt tccgactaa aagcagcttc gctttcggtt 6180
tgccagcgat attgcggaac acacggatga catcctgcac gcgtgcagcc actggtaaca 6240
ggattagcag agcagggtat gtaggcggtg ctacagagtt cttgaagtgg tggcctaact 6300
acggctacac tagaaggaca gtatttggt tctgcgctct gctgaagcca gttaccttcg 6360
gaaaaagagt tggtagctct tgatccggca aacaaaccac cgctggtagc ggtggttttt 6420
ttggttgcaa gcagcagatt acgcgcagaa aaaaaggatc tcaagaagat cctttgatct 6480
tttctacggg gtcgtacgct cagtggaaacg aaaactcacg ttaagggaatt ttggtcatga 6540
gattatcaaa aaggatcttc acctagatcc ttttaaatga aaaatgaagt tttaaatcaa 6600
tctaaagtat atatgagtaa acttggctct acagttacca atgcttaate agtgaggcac 6660
ctatctcagc gatctgtcta tttcgttcat ccatagtgc ctgactcccc gtcgtgtaga 6720
taactacgat accggaggggc ttaccatctg gccccagtc tgcaatgata ccgcgagacc 6780
cacgctcacc ggctccagat ttatcagcaa taaaccagcc agccggaagg gccgagcgca 6840
gaagtggctc tgcaacttta tccgctccta tccagctcat taattgttgc cgggaagcta 6900
gagtaagttag ttgcgcagtt aatagtttgc gcaacgttgt tgccattgct acaggcatcg 6960
tgggtgtcacg ctctcggttt ggtatggctt cattcagctc cggttcccaa cgatcaaggc 7020
gagttacatg atcccccatg ttgtgcaaaa aagcggttag ctccctcggt cctccgatcg 7080
ttgtcagaag taagtggcc gcagtgttat cactcatggt tatggcagca ctgcataatt 7140
ctcttactgt catgccatcc gtaagatgct tttctgtgac tggtagtac tcaaccaagt 7200
cattctgaga atagtgtatg cggcgaccga gttgctcttg cccggcgctc atacgggata 7260
ataccgcgcc acatagcaga actttaaaag gtctcatcat tggaaaacgt tottcggggc 7320
gaaaactctc aaggatctta ccgctgttga gatccagttc gatgtaacc actcgtgac 7380
ccaactgatc ttcagcatct tttactttca ccagcgtttc tgggtgagca aaaacaggaa 7440
ggcaaaatgc cgcaaaaaag ggaataaggc cgacacggaa atgttgaata ctcatactct 7500
tcctttttca atattattga agcattttatc aggggttattg tctcatgagc ggatacatat 7560
ttgaattgat ttagaaaaat aaacaaatag ggggtccgag cacattttcc cgaaaagtgc 7620
cacctgacgt ctaagaaacc attattatca tgacattaac ctataaaaaat aggcgtatca 7680
cgaggccctt tctctctgca tgcggatcag tgagggtttg caactgcggg tcaaggatct 7740
ggatttcgat cacggcacga tcatcgtgcg ggagggcaag ggctccaagg atcgggcctt 7800
gatgttacc gagagcttg caccagcct gcgcgagcag gggaattgat ccggtggatg 7860
accttttgaa tgacctttaa tagattatat tactaattaa ttggggaccc tagaggtccc 7920
cttttttatt ttaaaaaatt tttcacaaaa cgggtttacaa gcataacggg ttttgctgcc 7980
cgcaaacggg ctgttctggt gttgctagtt ttgtatcaga atcgagatc cggcttcagg 8040
tttgccggct gaaagcgcta tttcttccag aattgccatg attttttccc cacgggaggc 8100
gtcactggct cccgtgttgt cggcagcttt gattcgataa gcagcatcgc ctgtttcagg 8160
ctgtctatgt gtgactgttg agctgtaaca agttgtctca ggtgttcaat ttcattgtct 8220
agttgctttg ttttactggt ttcacctgtt ctattaggtg ttacatgctg ttcattctgt 8280
acattgtcga tctgttcag gtgaacagct ttaaatgcac caaaaactcg taaaagctct 8340
gatgtatcta tcttttttac accgttttca tctgtgcata tggacagttt tccctttgat 8400
atctaacggt gaacagttgt tctacttttg tttgttagtc ttgatgcttc actgatagat 8460
acaagagcca taagaacctc agatccttcc gtatttagcc agtatgttct ctagtgtggt 8520
tcgttgtttt tgcgtgagcc atgagaacga accattgaga tcatgcttac tttgcatgct 8580
actcaaaaat tttgcctcaa aactggtgag ctgaattttt gcagttaaag catcgtgtag 8640
tgtttttctt agtccgttac gtaggttaga atctgatgta atggtgtgtg gtattttgtc 8700
accattcatt tttatctggt tgttctcaag ttcggttacg agatccattt gtctatctag 8760
ttcaacttgg aaaatcaacg tatcagtcgg gcggcctcgc ttatcaacca ccaatttcat 8820
attgctgtaa gtgtttaaat ctttacttat tgggtttcaa acccattggt taagcctttt 8880
aaactcatgg tagttatttt caagcattaa catgaactta aattcatcaa ggctaattct 8940
tatatttgcc ttgtgagttt tcttttgtgt tagttctttt aataaccact cataaatcct 9000
catagagtat ttgttttcaa aagactttaa atgttccaga ttaattttta tgaatttttt 9060
taactggaaa agataaggca atatctcttc actaaaaact aattctaatt tttcgcttga 9120
gaacttgga tagtttgtcc actggaaaat ctcaaagcct ttaaccaaag gattcctgat 9180
ttccacagtt ctctcatca gctctctggt tgcttttagc aatacaccat aagcattttc 9240
cctactgatg ttcacatct gagcgtattg gttataagtg aacgataccg tccgttcttt 9300

```

ccttgtaggg ttttcaatcg tgggggttgag tagtgccaca cagcataaaa ttagcttggt 9360  
 ttcattgctcc gtttaagtcatt agcgactaat cgctagttca ttgctttga aaacaactaa 9420  
 ttcagacata catctcaatt ggtctagtg attttaatca ctataccaat tgagatgggc 9480  
 tagtcaatga taattactag tctttttcct ttgagttgtg ggtatctgta aattctgcta 9540  
 gacctttgct ggaaaacttg taaattctgc tagaccctct gtaaattccg ctagaccttt 9600  
 gtgtgttttt ttgttttata ttcaagtggg tataatttat agaataaaga aagaataaaa 9660  
 aaagataaaa agaataagatc ccagccctgt gtataactca ctactttagt cagttccgca 9720  
 gtattacaaa aggatgtcgc aaacgctgtt tgctcctcta caaaacagac cttaaaaccc 9780  
 taaaggctta agtagcacc cgcgaagctc gggcaaatcg ctgaatattc cttttgtctc 9840  
 cgaccatcag gcacctgagt cgctgtcttt ttcgtgacat tcagttcgct gcgctcacgg 9900  
 ctctggcagt gaatgggggt aaatggcact acaggcgct tttatggatt catgcaagga 9960  
 aactacccat aatacaagaa aagcccgtca cgggcttctc agggcggttt atggcgggtc 10020  
 tgctatgtgg tgctatctga ctttttgctg ttcagcagtt cctgccctct gattttccag 10080  
 tctgaccact tcggattatc ccgtgacagg tcattcagac tggctaagtc acccagtaag 10140  
 gcagcgggtat catcaacagg cttaccctgc ttactgtcaa c 10181

&lt;210&gt; 9

&lt;211&gt; 194

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; promoter sequence

&lt;400&gt; 9

gctattgacg acagctatgg ttcactgtcc accaaccaaa actgtgctca gtaccgcaa 60  
 tatttctccc ttgaggggta caaagagggtg tccctagaag agatccacgc tgtgtaaaaa 120  
 ttttacaaaa aggtattgac tttccctaca ggggtgtgtaa taatttaatt acaggcgggg 180  
 gcaaccccg cgt 194

&lt;210&gt; 10

&lt;211&gt; 163

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; promoter sequence

&lt;400&gt; 10

gcctacctag cttccaagaa agatattccta acagcacaag agcggaaaga tgttttgctc 60  
 tacatccaga acaacctctg ctaaaattcc tgaaaaattt tgcaaaaagt tgttgacttt 120  
 atctacaagg tgtggtataa taatcttaac aacagcagga cgc 163

&lt;210&gt; 11

&lt;211&gt; 127

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; promoter sequence

&lt;400&gt; 11

gaggaatcat agaattttgt caaaataatt ttattgacaa cgtcttatta acgttgatat 60  
 aatttaaat ttatttgaca aaaatgggct cgtgtgtgac aataaatgta gtgaggtgga 120  
 tgcaatg 127

&lt;210&gt; 12

&lt;211&gt; 42

&lt;212&gt; DNA

60367863-032502

<213> Artificial Sequence

<220>

<223> ribosome binding site

<400> 12

gaaatcatat aactatacct tgattagggg gaccaagaaa tg

42

<210> 13

<211> 42

<212> DNA

<213> Artificial Sequence

<220>

<223> ribosome binding site

<400> 13

caagaacgcg gctggtaga acataggagc gctgctgaca tg

42

<210> 14

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> ribosome binding site

<400> 14

tctagaaagg aggtga

16

<210> 15

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> ribosome binding site

<400> 15

tctagaagga ggagaaaaca tg

22

<210> 16

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> ribosome binding site

<400> 16

tctagaggag gagaaaacat g

21

<210> 17

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> ribosome binding site

<400> 17

20250704 16036784.032502



taagaacaaa ggaggagagc tgacatg

27

<210> 18

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> ribosome binding site

<400> 18

taagaacaga ggaggagagc tgacatg

27

<210> 19

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> ribosome binding site

<400> 19

taagaagaaa ggaggtgagc tgacatg

27

60367863.032502